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1. LIST OF ABBREVIATIONS 
 
- BMI: body mass index 
 
- BSTc: bed nucleus of the stria terminalis 
  
- CAH: congenital adrenal hyperplasia 
 
- DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, edition IV 
 
- FMT: female-to-male transsexuals 
  
- GID: Gender Identity Disorders 
 
- HRT: hormone replacement therapy 
 
- HT: hormone therapy  
 
- ICD-10: International Statistical Classification of Diseases and Related Health  
 
   Problems 10th Revision 
 
- LH: luteinizing hormone 
 






















2.1 Definition of transsexualism 
 
The first definition of the term transsexualism was established in 1953 by 
Benjamin, an endocrinologist and sexologist who published one of the first scientific 
articles on the topic [1]. He defined transsexualism as the condition where biological 
normality coexists with the belief of belonging to the opposite sex. Transsexual 
people are characterized by a desire for sex reassignment. For all these reasons, 
their disorder appears to be the most extreme case on the spectrum of gender 
identity abnormalities [2].  
 
 The International Statistical Classification of Diseases and Related Health 
Problems 10th Revision (ICD-10) states that transsexualism is defined by "the desire 
to live and be accepted as a member of the opposite sex, usually accompanied by 
the wish to make his or her body as congruent as possible with the preferred sex 
through surgery and hormone treatment" [3]. The Diagnostic and Statistical Manual 
of Mental Disorders, ed. IV (DSM-IV) accepts the expression of desire to be of the 
opposite sex, or assertion that one is of the sex opposite to the sex one was 
assigned at birth, as sufficient for being transsexual [4]. This manual uses the term 
“Gender Identity Disorders” (GID) to refer to transsexualism.  
 
The photographer Georges Jorgensen was the first transsexual who 
underwent surgery for sex change. The operation was performed by a Danish team 
and included hormone administration and postoperative follow-up [5]. After this case 









2.2  Epidemiology 
 
The prevalence of transsexualism varies depending on the country and year. 
Not all transsexuals contact specialized services, as some are treated illegally or by 
independent doctors. Therefore the prevalence rates reported are most likely to be  
imprecise [2, 6] . 
DSM-IV analysed the results from different reports and found an average 
prevalence of 1:30 000 men and 1:100 000 women [4]. Table 1 shows the results of 
the different prevalence studies. 
 
Study Country MFT FMT Total 
Walinder 1968 Sweden 1:37 000 1:103 000 1:54 000 
Pauly 1968 USA 1:100 000 1:400 000  
Hoenig & Kenna 1974 England 1:34 000 1:108 000 1:53 000 
Ross et al. 1981 Australia 1:24 000 1:150 000 1:42 000 
O'Gorman 1982 Ireland 1:35 000 1:100 000 1:52 000 
Eklund et al. 1988 The Netherlands 1:18 000 1:54 000  
Tsoi 1988 Singapore 1:2900 1:8300  
Bakker et al. 1993 The Netherlands 1:11 900 1:30 400  
Weitze & Osburg 1996 Germany 1:42 000 1:104 000 1:48 000 
 
Table 1: Prevalence of transsexualism in different countries, in chronological order of reports. MFT: 
male-to-female transsexuals, FMT: female-to-male transsexuals [2]. 
 
 
2.3  Etiology   
 
 The etiology of transsexualism remains uncertain, but different hypotheses 
exist. Some studies have tried to explain the origin of these disorders from a 
biological point of view while others have hypothesized a psycho-social cause of the 
problem. 
  
 At the beginning of this century, it became clear that the process of sexual 
differentiation is not completed with the formation of the external genitalia, but that 
the brain also undergoes a differentiation into male or female [7]. The brain 
differentiates into a male brain during the critical period of sexual differentiation with 
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sufficient amounts of testosterone, and it becomes female in the absence of 
testosterone. Animal studies have revealed that certain brain nuclei are influenced by 
the presence of testosterone [8]. 
  
 Biological research on transsexualism addresses three areas. The first area of 
research refers to abnormalities in perinatal endocrinological history. A few cases 
have been studied of girls that were biological females but with congenital adrenal 
hyperplasia (CAH), a disease that causes prenatal exposure to relatively high levels 
of androgens. These females were raised as girls, but developed a male gender 
identity [9].  It is not common for CAH girls who were assigned and raised as girls to 
become transsexuals [10, 11], however, in some studies some atypical gender 
behaviour was found. On the other hand, transsexualism was not found in men or 
women exposed to progestagens (which may have antiandrogenic or androgenic 
properties) in their prenatal phase, nor was it found after exposure to estrogenic 
drugs, such as diethylstilbestrol [10, 12].   
The second area of research is based on the assumption that the luteinizing 
hormone (LH) can be used as an indicator of sexual differentiation of the brain. There 
have been studies showing that in male-to-female transsexuals (MFT), just like in 
females, the LH level rises after estrogen stimulation, as a result of prenatal exposure 
to imbalanced steroid levels. The opposite was expected to happen in female-to-male 
transsexuals (FMT) [13, 14]. Nevertheless other studies were not able to replicate 
these results [15, 16] 
Studies on sexual dimorphic brain nuclei in transsexuals constitute the third 
line of research on biological causes of transsexualism. Hypothalamic nuclei such as 
a sexually dimorphic nucleus of the pre-optic area of the hypothalamus (SDN-POA), 
two cell groups in the anterior hypothalamus (INAH-2 and INAH-3), the dark staining 
posteromedial component of the bed nucleus of the stria terminalis (BNST-dspm), the 
suprachiasmatic nucleus (SCN), and the central subdivision of bed nucleus of the 
stria terminalis (BSTc) have all been reported to be different in males and females. It 
is possible that the differences between male and females in these nuclei may 
explain sex characteristics in gender identity, sexual orientation and other 
reproductive aspects [14]. It was found that the BSTc is equal in size in MFT and in 
females and a female brain structure was shown in biological male transsexuals [7].  
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Apart from the constitutional and endocrinological factors that have been 
studied and related to transsexualism, it is also possible that other psychological and 
social aspects contribute to the condition [2]. Different psychological theories exist, 
such as the non-conflictual hypothesis and the conflictual hypothesis [17, 18]. In the 
former, transsexualism appears to be the result of a non-conflictual process, where 
gender identity is fixed from early infancy. The conflictual hypothesis considers 
transsexualism as a conflictual process, where gender identity rather continues to be 
ambiguous throughout the patient´s life. 
 
 
2.4  Diagnosis and differential diagnosis 
 
DSM-IV stipulates five criteria that must be met before a diagnosis of GID can 
be given [4]: A. There must be evidence of a strong and persistent cross-gender 
identification. B. This cross-gender identification must not merely be a desire for any 
perceived cultural advantages of being the other sex. C. There must also be 
evidence of persistent discomfort about one's assigned sex or a sense of 
inappropriateness in the gender role of that sex. D. The individual must not have a 
concurrent physical inter-sexual condition (e.g., androgen insensitivity syndrome or 
congenital adrenal hyperplasia). E. There must be evidence of clinically significant 
distress or impairment in social, occupational, or other important areas of functioning. 
 
Disturbances such as chromosomal alterations (Klinefelter syndrome, Turner 
syndrome, hermaphroditism vero, etc), gonadal alterations (pure gonadal dysgenesia 
and “absent testicle syndrome”) and endocrine alterations (feminine 
pseudohermaphroditism by congenital adrenal hyperplasia and alterations of the 
development of the müllerian structures; masculine pseudohermaphroditism by 
anomalies in androgens synthesis, androgen action anomalies and persistent 
müllerian conducts syndrome) have to be excluded [4].  
 
 Apart from these diseases, mental disorders such as “cross dressing and 
transvestism”, psychosis, and gender identity disturbance in the frame of teenager 





  The treatment for transsexual people encompasses five steps. In the first 
phase the diagnosis has to be confirmed by performing genetic, endocrinological and 
internal medicine tests and excluding a hermaphroditismus vero or 
pseudohermaphroditism. In parallel the patient undergoes psychotherapy to prepare 
for the subsequent sex changes. In the next phase, called “Daily-life-test”, the 
patients test the opposite gender role and consolidate their experience of it. Cross-
sex hormone therapy (HT) is initiated before the last step, cross-sex surgery, takes 





 Gender identity disorders create a stress that often leads to anxiety and 
depression. Hence, psychotherapy plays an important role by supporting the patients 
and giving them the opportunity to express their anxieties and fears [19]. 
The type of psychotherapy or gender of the therapist is not crucial, as long as 
the contact is of good quality.  
Finally, to emphasize the role of the psychotherapy, it is interesting to point out 
that a review of the literature has identified psychotherapeutic help as one of seven 
factors that lead to a favourable overcome in the treatment of transsexuals [20]. 
 
 
2.5.2 Hormone therapy   
 
Cross-sex HT is an important part of the medical treatment for transsexual 
patients. It provides a relief for these patients because it helps them to obtain some 
of the corporal characteristics of their desired gender and prepares the body for the 
final changes that will be achieved by the surgical interventions.  
There are few studies on hormonal treatment outcomes in transsexuals and 
therefore management remains for the moment complex and guided by practical 
experience. It is also a fact that cross-sex HT has health risks, nevertheless these 
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risks have to be balanced with the psychopathological gender identity request of 
these patients.  
 
 
2.5.2.1 Endocrine treatment regimes 
 
(a) Masculinizing endocrine treatment regimens of FMT 
 
Testosterone is the hormone that will give FMT the secondary sexual 
characteristics of the masculine gender.  
Usually injectable testosterone is used alone, both before and after 
oophorectomy. Oral testosterone undecanoate, available outside of the United 
States, has been associated with more consistent but lower serum testosterone 
levels, but it may not suppress menstruation without the addition of a progestin. GH-
releasing hormone agonists have been used in adolescent transsexual people to 
delay puberty, in order to postpone cross-sex HT until adulthood with less 
psychological stress to the individual. Transdermal applications reach physiological 
testosterone better than the other methods of treatment. 
The dose of testosterone to be given varies from one patient to another, but 
blood levels should be close to the normal male value of 500 µg/dl.  
 
For FMT different regimens of HT are practised in different institutions. In the 
Endocrine Outpatient Clinic of the Max Planck Institute (Munich, Germany), the 
practice is to administer testosterone esters, 250 mg intramuscular every 2 weeks, 
then reduce the dosage in 9–12 months after desired effects to every 2–4 weeks. 
Optionally progesterone is used, 500 mg intramuscular, two doses 3–4 days apart 
between testosterone doses [21, 22]. 
 
(b) Feminizing endocrine treatment regimens of MFT 
 
The treatment regimens for MFT include various forms of estrogens, 




Estrogen (such as 17β-Estradiol) is the basis for the treatment of MFT. The 
recommended dose is two to three times as high as for hormone replacement 
therapy (HRT) in postmenopausal women. Oral application is used by most clinics 
but transdermal and intramuscular formulations also exist. Transdermal estrogens 
are given in some clinics in patients older than 40 years of age, because of the 
association with thromboembolic events [24, 25]. Higher doses of estrogens or 
intramuscular formulations are used in some circumstances for short periods of time. 
In these cases, indications include an inability to lower serum testosterone to 50 
µg/dl.  Estrogen doses are lowered in patients with cardiac or other comorbidities or 
when adverse effects appear. High doses are avoided to minimize adverse effects. 
After gonadectomy, all clinics maintain estrogen therapy in order to preserve female 
features and bone mineral density. 
 
The concurrent administration of antiandrogens and progestins may enhance 
the effects of estrogens.  
In principle, antiandrogens lower serum levels of testosterone or block its 
binding to the androgen receptor, thereby decreasing masculine secondary sexual 
characteristics. Several studies reported lowering of testosterone with cyproterone 
acetate 100 µg/d [26]. A synergistic effect with estrogen on the physical and 
emotional changes was also reported with spironolactone [27]. This is helpful in 
patients with comorbidities in whom high levels of estrogens should be avoided. GH-
releasing hormone agonists have also been considered by some to increase 
estrogen effects when risk factors limit the dose of estrogen [28]. 
The use of progesterone in addition to estrogens in the treatment of MFT is 
advocated by some because it was observed to enhance breast growth and decrease 
irritability and breast sensitivity. However, the clinical effect of progestins was not 
evident in small observational studies [29]. Nevertheless, treatment with progestins 
has to be done carefully, as reported by the Women’s Health Initiative study [30]. 
Combined estrogen and progestin therapy increase the risk of coronary heart 
disease, strokes, pulmonary embolism, and invasive breast cancers in 
postmenopausal women on HRT. The use of a progestin for long periods should be 
avoided to prevent similar adverse effects in transsexual people. 
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Different hormonal regimens are practised in the treatment of pre-surgical 
transsexual people, depending on the clinic. In the Endocrine Outpatient Clinic of the 
Max Planck Institute (Munich, Germany) the regimen consists of 17ß-estradiol 2–8 
mg/d and cyproterone acetate 100 mg/d for 6–12 months until testosterone is 
lowered [21, 22]. 
 
 
2.5.2.2 Effects of the hormonal therapy 
 
(a) Effects of masculinizing treatments in FMT 
 
The negative effects and risks of the administration of androgens in 
transsexual people have not been well assessed due to the relatively small number 
of patients. Retrospective data in some studies report no change in mortality, but the 
population may not be large enough to detect differences [24].  
 Polycythemia is a complication of treatment with testosterone already known 
from biological males. The combination of increased weight, decreased insulin 
sensitivity, poor lipid profile and an increase in hematocrit has been described in 
FMT, and this predisposes theoretically to cardiac and thromboembolytic events. In 
fact, case reports of cerebral vascular accidents have been reported for individuals 
with supra-physiological levels of testosterone [31]. 
 Polycystic ovaries are reported in many FMT before being treated with 
androgens [31, 32], and this disease is a risk factor for endometrial cancer. Also 
endometrial hyperplasia has been observed after hysterectomies in patients treated 
with exogenously administered testosterone [33]. A case report of two transsexual 
people with ovarian cancer raised the question of an association with the hormonal 
treatment [34]. In order to avoid these negative effects, some clinicians advocate a 
hysterectomy after two years of therapy, followed by an important reduction in 
testosterone [2]. 
The reported positive and negative effects of hormonal treatment in FMT are 





Positive effects of masculinizing  
treatments in FMT 
Negative effects of masculinizing  
treatments in FMT 
 
  - Deepened voice 
  - Cessation of menses 
  - Hirsutism 
  - Clitoral growth 
  - Laryngeal prominence 
  - Increased libido 
  - Breast atrophy (histological) 
  - Redistribution of fat 
  - Testosterone to male levels 




- Weight increase > 10% 
- Elevated liver enzymes 
- Increased hematocrit 
- Endometrial hyperplasia 
- Sleep apnea 
- Aggression, hypersexuality 
- Poor lipid profile 
- Decreased insulin sensitivity 
- Increased insulin-like growth factor (IGF) 
- Decreased bone density 
- Ovarian cancer 
 
 
Table 2: Effects and side effects of hormonal treatment regimes in FMT with intramuscular, oral or 
transdermal testosterone [23].  
 
 
(b) Effects of feminizing treatments in MFT 
 
The side effects of sex hormonal therapy cannot be underestimated. The most 
frequent side effect is a greatly increased risk (by 20 times) of venous thrombosis 
[24]. Another frequent phenomenon is an increase in prolactin levels [24, 35]. This 
increase in prolactin is associated with accelerated growth of prolactinomas in these 
patients [2, 36]. Measurement of prolactin levels as well as the status of the visual 
fields is recommended to detect this risk. Depression is also more frequent in 
comparison with the general population [25].  
 
A correlation exists between the dose of estrogens given to women for 
contraception and the risks of suffering from side effects like venous 
thromboembolytic disease, pulmonary embolism, myocardial infarction, stroke and 
adverse liver effects [37, 38, 39, 40]. It is possible that similar risks apply to 
transsexual people. Nevertheless no studies have yet clarified this issue well. 
Additionally, a higher risk of side effects in MFT under hormonal treatment can be 
assumed if they smoke, are over 35 years of age, or have other risk factors for 
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cardiovascular disease, just as has been observed in women who take oral 
contraceptives [41]. Therefore it is important to try to minimize the dose of estrogens, 
not only in older patients and those with comorbidities, but also in healthy and 
younger people. Smoking cessation, weight reduction, exercise, and appropriate diet 
are also recommended. 
 
Reported positive and negative effects of the hormonal treatment in MFT are 
summarized in Table 3.  
 
Positive effects of feminizing 
treatments in MFT 
Negative effects of feminizing  
treatments in MFT 
 
 - Gynecomastia 
 - Enlarged areolae and nipples 
 - Softened skin 
 - Reduced testicular volume 
 - Decreased spontaneous erections 
 - Decreased libido 
 - Redistribution of fat 
 - Calming effect 
 - Testosterone to female levels 
 - Decreased hair growth 
 
 
- Venous thrombosis 
- Cholelitiasis 
- Hyperprolactinemia 
- Elevated liver enzymes 
- Depression 
- Decrease in hemoglobin 
- Prolactinoma 
- Breast cancer 
- Prostatic carcinoma 
- Decreased insulin sensitivity 
- Decreased IGF 
 
 
Table 3: Effects and side effects of hormonal treatment regimes in MFT with oral, transdermal or 















 Surgical treatment is the final therapy which is undergone only after 
psychotherapy and at least 12 months of hormonal treatment.  
 
 2.5.3.1 Genital surgery in FMT 
 
 The genital surgery for the sex reassignment in FMT includes a hysterectomy, 
a double adnexectomy of the ovaries and Fallopian tubes and the phalloplasty [42]. 
The function of the hysterectomy and adnexectomy is to eliminate the secretion of 
estrogens and to avoid future alterations in the uterus and ovaries due to the 
treatment with androgens [43, 44]. The objective of the phalloplasty is to create 
external genitals with a masculine aspect that allow a normal mictional function and 
an erogenous stimulation.  
 The possible complications of the phalloplasty are due to the complexity of the 
technique. The usual ones are related to the urinary tract and the penis prothesis. 
Ischemy and dehiscences of the uretheral anasthomosis are frequent causes of 
fistules and uretheral stenosis [42]. 
 
 2.5.3.2 Genital surgery in MFT 
 
 For MFT patients, the surgical procedures in the genital organs include: the 
ablation of both of the testicles, the complete resection of the cavernose bodies, the 
shortening of the urethra, the conversion of the gland into a clitoris with preservation 
of the nerves and vessels, the construction of a vaginal hole in the space recto-
prostato-vesical and the construction of the vulvar lips from the scrotal skin [19].  
 Apart from the usual postoperative risks, in these cases there can also appear 
complications like damage of the urinary conducts and intestines or shrinkage of the 







2.5.4 Other additional therapies and surgeries 
 
 Another important surgical treatment is breast surgery. In MFT, it consists of 
the construction of a female breast with either expansors and silicone implants or 
with microfat transplants. For FMT, a subcutaneous mastectomy is required in most 
cases. 
 Also MFT patients may have logopedic treatment and eventually surgery in 




























3. AIM OF THE PROJECT 
 
We aimed at investigating: 
 
 - Underlying etiological factors in the clinical history of transsexual patients 
(such as intake of medications or diseases during the mother’s pregnancy, and 
abnormalities during birth, childhood or puberty) and possible genetic or hereditary 
predispositions in the family of the patient. 
 
 - Quantity and quality of side effects and comorbidities under hormonal 
treatment of transsexual patients. This will be done descriptively in the patient group 
alone and in comparison with an age- and gender-matched control group from the 
epidemiological DETECT cohort. Since gender is reassigned, our patient sample will 
be analysed against both, a female and a male age-matched control sample. 
 
- Satisfaction of transsexual patients with treatment modalities and treatment 
achievements or success. The level of somatic and psychologically perceived health 
will be evaluated for the different medical procedures and compared between FMT 

















4. MATERIALS AND METHODS 
 
 
4.1 Type of study 
  
 This study is a cross-sectional diagnostic study. The study lasted one year and 
took place between October 2007 and September 2008 (including the planning 
phase, recruitment of patients, acquisition of the data, the analysis and writing of the 
results). 





4.2.1 Patient sample 
 
Around 440 patients with the diagnosis “transsexualism” (F64.0, ICD-10) were 
treated at the Endocrine Outpatient Clinic of the Max Planck Institute for Psychiatry in 
Munich in the period between January 1996 and December 2007. They would visit 
the clinic every 6–12 months. Through the electronic database of the Institute, we 
identified the patients and invited them to participate in this study. Additionally, the 
clinicians and psychotherapists participating in the Qualitätzirkel (Quality Committee) 
that evaluated our questionnaire assisted us to contact some of their patients.  
Questionnaires were sent to almost all of these patients. Our study finally 
involved a sample of n = 95 patients with the diagnosis of transsexualism, of whom 
37 were FMT (average age 32 ± 9 years, average age at diagnosis 25 ± 8 years ) 
and 58 were MFT (average age 48 ± 11 years, average age at diagnosis 39 ± 12 
years). 
 
4.2.2 Inclusion and exclusion criteria 
   
 The inclusion criteria for this study were: patients over 18 years of age with the 
diagnosis of transsexualism in the Endocrine Outpatient Clinic of the Max Planck 
Institute for Psychiatry in Munich. Additional patients treated by clinicians of the 
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Qualitätzirkel were included. The patients had to be undergoing psychotherapy 
and/or HT and they may have undergone surgery. Additionally they had to sign a 
consent to allow use of their data in an anonymous way.  
 The exclusion criteria were: patients under 18 years of age or unwilling to 
participate. 
 
4.2.3 Comparison group 
 
In order to estimate the magnitude of the side effects and problems of the 
hormonal treatment in our transsexual patients, we used an age-matched control 
group of males and females sampled from the DETECT study (Diabetes 
Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of 
Treatment).  
DETECT is an epidemiological study of the Institute for Clinical Psychology 
and Psychotherapy of the Technical University Dresden, in cooperation with the Max 
Planck Institute for Psychiatry (Munich) and the university hospitals of Frankfurt, 
Magdeburg, Graz and Hamburg-Eppendorf (www.detect-studie.de). This study was 
designed to address critical issues on cardiovascular risk factors and it took place in 
primary care patients. In the study, 55,518 unselected patients completed a 
questionnaire on their demographic data, their complaints, their illness history, their 
knowledge about selected diseases and their attitude towards the diseases. A 
subsample of 7519 patients additionally attended a standardized laboratory 
screening programme, which was focused on blood constituents connected with 
cardiovascular diseases and diabetes. These patients were assessed a second time 
one year later. The study provides descriptive epidemiological information on 
frequency, characteristics, risks and treatment of cardiovascular diseases, as well as 











4.3.1 Design and validation of the questionnaire 
 
A review of the literature was performed in order to identify relevant 
information about etiological aspects, treatment protocols and side effects in 
transsexual patients. 
The first draft of the questionnaire was distributed to a small group of patients 
during the Selbsthilfegruppentag in June 2007. Afterwards, feedback was collected 
and a new revised version was developed and evaluated by the Qualitätzirkel 
Transsexualität in Munich (including psychiatrists, endocrinologists, surgeons, 
psychotherapists and logopedians). 
The final questionnaire was designed to have three parts (see attached 
document in the appendix): A. The first part contains socio-economic questions (age, 
occupation and other socio-demographic aspects). B. The second part has the 
structure of a clinical anamnesis and captures possible characteristics and causes of 
transsexualism. It includes questions about pregnancy of the mother, development in 
childhood, sexual orientation and previous or actual diseases of the patients and their 
families. C. In the last part, we included questions about the different regimes of 
treatment that the patient had undergone, to evaluate their efficiency and possible 
problems. We measured with a numerical scale the subjective level of satisfaction of 
the patients with all the medical procedures. A set of standardized questionnaires 
was included in our questionnaire measuring sleep alterations, such as the Pittsburgh 
Sleep Quality Index (PSQI), the Epworth Sleepiness Scale (ESS), a questionnaire for 
the evaluation of Restless Legs Syndrome, a questionnaire for the evaluation of 
respiratory problems related to sleep, parasomnia screening Munich and SCL 90-R. 
The questionnaire was evaluated by the department of epidemiological 
psychology of the Max Planck Institute of Psychiatry and sent to the patients in March 
2008. The response rate was 35 %. 
In the frame of this retrospective analysis, a database was created with 
Microsoft Access (Windows 2000), where we registered all this socio-demographic, 




4.4 Statistical analysis 
 
In the frame of the formulated hypothesis of the etiology and effects of the 
hormonal treatment, percentages of problems during the development of the patients 
were calculated, as well as frequencies of the effects under hormonal treatment. 
Finally, we measured with a numerical scale the subjective level of satisfaction of the 
patients with all the medical procedures and we calculated means and standard 
deviations. 
As statistical tests for the comparison between 2-groups (MFT and FMT, 
biological men and MFT, biological men and FMT, biological women and MFT, 
biological women and FMT), we estimated the mean and frequencies by the 
Wilcoxon Rank Sum test or Chi-square. For the comparison between more than two 


























5.1 Description of the patient group 
 
 In this study, a total number of 95 patients participated. The patients were 
classified into two major groups; MFT or FMT.  More than half of the participants 
were MFT (60.4%, n = 58), 37 patients of the total number of participants were FMT 
(38.5%). 
The average age of the MFT at the time of the study was 48 ± 11 years and 
FMT patients had an average age of 32 ± 9 years (p<0.001). Average body mass 
index (BMI) value for MFT was 25.1 ± 4.8 kg/m2 and 24.8 ± 4.5 kg/m2 for FMT 
(p=0.872) (Table 4). 
In relation to the levels of education, we observed that almost the same 
percentage of FMT (13.5 %) and MFT (13.8 %) had a university degree. In FMT, the 
largest group of patients (35.1 %) had a Berufsfachschulabschluss, 16.2 % were in 
education, 10.8 % had no professional education, 8.1 % had a Facharbeiter-
Abschluss and 2.7 % had a Fachhochschulabschluss. In MFT, 27.6 % had a 
Facharbeiter-Abschluss, 20.7 % a Berufsfachschulabschluss and 24.1 % a 
Fachhochschulabschluss (p = 0.004) (Table 4). 
 
 FMT (n = 37) MFT (n = 58) p 
 Mean SD Mean SD  
Age 31.7 8.9 48.0 11.5 <0.001 
BMI 24.8 4.5 25.1 4.8 0.872 
School years 11.2 1.5 11.1 2.4 0.564 
Professional education n % n %  
       - none 4 10.8 4 6.9 0.004 
    - in education 6 16.2 3 5.2 0.004 
    - Facharbeiter 3 8.1 16 27.6 0.004 
    - Berufsfachschule 13 35.1 12 20.7 0.004 
    - Fachhochschule 1 2.7 14 24.1 0.004 
    - Hochschule 5 13.5 8 13.8 0.004 
 




The average number of years of school education in the FMT sample was 
11.2 ± 1.5 and 11.1 ± 2.4 for the MFT (p=0.564). In our group of patients, 40.5 % 
FMT vs. 19.0 % MFT had a school graduation of Mittlere Reife in the German 
educational system; 32.4 % FMT vs. 29.3 % MFT had Abitur graduation; 16.2 % FMT 
vs. 31.0 % MFT had Hauptschuleabschluss; 5.4 % FMT vs. 13.8 % MFT had 
Fachoberschuleabschluss  and 2.7 % FMT vs. 5.2 % MFT had no school graduation  


























5.2 Early clinical history 
 
 More than half of the patients did not report an intake of hormones or other 
medication during their mother’s pregnancy (67.6% FMT vs. 51.7% MFT). A high 
percentage of patients could not confirm this information (24.3 % FMT vs. 46.5 % 
MFT) (p = 0.047). 
 Only 13.5 % of FMT and 8.6 % of MFT reported peculiarities during their 
mother’s pregnancy. A large proportion, 27 % FMT vs. 46.5 % MFT did not report 
information related to this point (p = 0.159). 
 In 51.3% of FMT and 44.8% of MFT there were no reported peculiarities 
during their birth. Nevertheless 37.8% of FMT and 22.4% of MFT respectively 
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reported some problems, though not different ones from the normal population (p = 
0.037). 
 In relation to childhood and puberty, 54.0% and 56.7% of FMT reported that 
there were no peculiarities in their childhood and puberty, respectively. In MFT, the 
percentages were 51.7% and 56.9% respectively. In the group of FMT, 21.6% and 
27.0% answered that there were alterations in their childhood and puberty. The 
percentages were 32.7% and 24.1% respectively for childhood and puberty in MFT. 
The rest of the patients reported that they do not know (p = 0.380 for childhood and 
p= 0.918 for puberty). 
 A summary of the findings about patients’ early history is given in Table 5. 
 
 FMT (n = 37)       MFT (n = 58) p 
 n % N %  
Intake of  medications       
yes 3 8.1 1 1.7 0.047 
no 25 67.6 30 51.7 0.047  
not known 9 24.3 27 46.5 0.047 
Alterations in pregnancy       
yes 5 13.5 5 8.6 0.159 
no 22 59.4 26 44.8 0.159 
 
not known 10 27.0 27 46.5 0.159 
Alterations in birth       
yes 14 37.8 13 22.4 0.037 
no 19 51.3 26 44.8 0.037 
               
not known 4 10.8 19 32.7 0.037 
Alterations in childhood       
yes 8 21.6 19 32.7 0.380 
no 20 54.0 30 51.7 0.380 
               
not known 9 24.3 9 15.5 0.380 
Alterations in puberty       
yes 10 27.0 14 24.1 0.918 
no 21 56.7 33 56.9 0.918 
               
not known 6 16.2 11 19.0 0.918 
 





Average age of menarche in FMT was 12.8 ± 1.5 years and 29.7 % had  
abnormal menstruation subsequently. 
 
 A high percentage of the patients (67.7 %) knew their chromosomal sex, which 
means that they had undergone a chromosomal analysis test. Out of the 37 FMT, 12 
(32.4 %) did not know their chromosomal sex, and the other 25 (67.6%) were 
biological females (46 XX in chromosomal analysis). Nineteen of the 58 MFT (32.7%) 
did not know their chromosomal sex, 38 (65.5%) were biological males (46 XY). 
None of the patients of our sample reported belonging to the group of patients with 
Klinefelter syndrome (47, XXY) or Turner syndrome (45, X0). 
 
 
5.3 History of transsexualism 
 
 In FMT, the average age when they realized their gender disorder was 8.5 ± 
5.0 years. In MFT this fact happened later (12.6 ± 9.3 years) (p = 0.007). In both 
cases, the different ages correspond to the beginning of puberty. 
 Interestingly, in FMT patients the diagnosis of transsexualism was at 24.7 ± 
7.8 years, whereas the average age of diagnosis in MFT was later (38.6 ± 11.7 
years) (p < 0.001). 
 FMT started living in the opposite gender role at an average age of 23.4 ± 
10.5. MFT patients reported having started living in the opposite sex role later, with 


























Figure 2:  Average age when the patients first noticed their condition (“First 
noticed”), when they started living in the opposite sex role (“Role”) and the 
diagnosis was made (“Diagnosis”). 
 
 
 For the majority of FMT, parents and friends realized their condition first: in 
43.2 % the mother, in 27.0 % the father, in 37.8 % friends and in 10.8 % other 
members of the family (not parents). In a small percentage of patients, it was others 
who first noticed their condition; a partner (5.4 %), at school (5.4 %), at work (5.4 %) 
and other known people (5.4 %) (Table 6). 
    In comparison with FMT, MFT showed a different pattern: 18.9 % of MFT 
related that it was their mother who first realized their condition, 10.3 % the father, 
18.9 % friends and 13.8 % other family members. Interestingly, 27.6 % reported that 
no one realized (Table 6). 
Amongst the reasons why FMT patients or people around them noticed their 
gender dysphoria were abnormal behaviour and the wish to wear masculine clothes. 
Other reasons mentioned were a negative feeling about their own body, the belief 
that they were not in the correct gender role in society and a wish to change, the 
perception of belonging to the opposite sex, having masculine interests and feeling 
like a man, and even in some cases experiencing psychological problems and 
feelings of fear.  
 In comparison with FMT, MFT also reported having feminine behaviour and 
the wish of wearing women clothes, but in MFT the latter was more remarkable. In 
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general, MFT reported a greater variety of reasons why they noticed their condition. 
Amongst them were described the feeling of being in a false body or the negative to 
their own body, feminine interests and the wish to have a feminine role in society.  
 
 FMT (n = 37) MFT (n = 58) 
 n % n % 
Mother 16 43.2 11 19.0 
Friends 14 37.8 11 19.0 
Father 10 27.0 6 10.3 
Family (others) 4 10.8 8 13.8 
Everybody 3 8.1 0 0 
Nobody 3 8.1 16 27.6 
Partner 2 5.4 5 8.6 
Work 2 5.4 1 1.7 
School 2 5.4 2 3.4 
Other known people  2 5.4 1 1.7 
Not known 2 5.4 1 1.7 
Not answer 2 5.4 9 15.5 
 




We found that a high number of the FMT (83.8 %) reported having changed 
their names, while the percentage of the MFT was lower (72.4 %) (p=0.199).  
 On the other hand, a lower percentage of both the FMT (59.4 %) and MFT 
(48.3%) had changed their personal stand at the time of the study (p=0.371). 














In FMT, 70.3 % of our patients were sexually oriented to women, 18.9 % to 
men, 5.4% to both sexes and 5.4 % were undecided. Interestingly, 34.5 % of MFT 
were also sexually oriented to women, 24.1 % to men, 22.4 % to both and 13.8 % 
were undecided (p=0.008) (Table 7). 
A woman is the chosen partner for 89.5 % of FMT who had a long-term 
partner. Surprisingly, 72.0 % of MFT chose a woman and 24.0 % a man (p=0.242) 
(Table 7). In FMT, 71.4 % of the participants reported that their partner was sexually 
oriented to men, 14.3 % to women and 14.3 % to both sexes. In MFT, 53.3 % 
reported that their partner was sexually oriented to men (p=0.189), 36.7 % to women 
(p=0.145) and 10.0 % to both sexes (p=0.566) (Table 7). 
Finally, 78.4 % of FMT and 37.9 % of MFT reported being single. A lower 
percentage of FMT (10.8 %) and MFT (22.4 %) were married to a woman. In the 
group of FMT, 8.1% were divorced or separated and 2.7 % had a civil partnership. 
No MFT had a civil partnership and 39.6 % were divorced or separated (p<0.001) 
(Table 7). 
One of the FMT had given birth and 53.4 % of MFT were biological fathers 

















       FMT (n = 37)       MFT (n = 58) P 
  n % n %  
SO       
     - to men 7 18.9 14 24.1 0.008 
     - to women 26 70.3 20 34.5 0.008 




      - undecided 2 5.4 8 13.8 0.008 
Partnership       
      - no partnership 18 48.6 33 56.9 0.432 
      - with man 1 2.7 6 10.3 0.242 
 - with woman 17 45.9 18 31.0 0.242 





      - with FMT 0 0 0 0 0.242 
Partner’s SO            
      - no answer 16 43.2 28 48.3 0.631 
      - to men 15 40.5 16 27.6 0.189 




      - to both 3 8.1 3 5.2 0.566 
CS       
      - single 29 78.4 22 37.9 0.000 
- married to man 0 0 0 0 0.000 
   - married to woman  4 10.8 13 22.4 0.000 
      - divorced/separated 3 8.1 23 39.6 0.000 






       - widow 0 0 0 0 0.000 
 
Table 7: Percentage and absolute number of patients classified in terms of sexual orientation (SO), 





The prevalence of present and past diseases in FMT was distributed as 
follows: psychiatric 24.3 %, gastrointestinal 21.6 %, endocrine 18.9 %, cardiovascular 
13.5 %, respiratory 13.5 %, immune mediated 8.1 %, musculoskeletal 8.1 %, sexual 
5.4 %, urinary 5.4 %, tumoral 5.4 %, neurological 2.7 % and haematological 2.7 % 
(Figure 3). 
In MFT, 19.0% had a history of respiratory diseases (p = 0.489), 19.0 % of 
endocrine diseases (p = 0.995), 19.0 % psychiatric (p = 0.532), 17.2 % 
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gastroenterological (p = 0.595), 15.5 % cardiovascular (p = 0.788), 15.5 % 
neurological (0.047), 15.5 % musculoskeletal (p = 0.289), 10.3 % haematological (p = 
0.164), 8.6 % immune mediated (p = 0.930), 8.6 % sexual (p = 0.559), 6.9 % urinary 
(p = 0.771) and 3.4 % tumoral diseases (p = 0.643) (Figure 3). 
 























Figure 3: Percentage of FMT in comparison with MFT that presented lifelong comorbidities at the time 
of the study. The comorbidities are categorized by general type of disease.   
 
 
It is interesting to point out that two patients reported the same congenital 
disease, adrenogenital syndrome. This condition may have caused the ambiguity of 
sexual development and led to the actual sexual identity disorder. One patient in our 
study was born with abnormalities in development of the sexual organs and another 
one excluded from our study because her hermaphrodite condition. 
 
 We compared the lifetime comorbidities in our patient sample with an age-
matched cohort (1:3) from the DETECT study.  
 Comparing lifetime comorbidities of FMT with an age-matched group of 
females, we found 17.2 % FMT to 12.5 % females of the same average age for 
cardiovascular diseases (p = 0.531). For respiratory diseases, 17.2 % FMT to 9.7 % 
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females (p = 0.857). For neurological diseases, 3.5 % FMT to 13.9 % females (p = 
0.001). For hormonal and metabolic diseases, 17.2 % FMT to 47.2 % females (p = 
0.369). For gastroenterological diseases, 24.1 % FMT to 12.5 % females (p = 0.298). 
For urinary diseases, 6.9 % FMT to 6.9 % females (p = 0.001). For tumoral diseases, 
6.9 % FMT to 11.1 % females (p = 0.504). For psychiatric disorders, 34.5 % FMT to 
38.9 % females (p = 0.656). For immune mediated diseases, 6.9 % FMT to 6.9 % 
females (p < 0.001). In relation with smoking status, we found 24.1 % of FMT 
smoked to 31.8 % of female smokers (p = 0.023). Regarding alcohol consumption, 
we found 13.8 % FMT to 74.6 % females (p < 0.001). BMI was 25.4 ± 4.8 in FMT vs. 
24.9 ± 5.2 in females (p = 0.302). Number of education years was 11.3 ± 1.6 in FMT 
vs. 11.5 ± 1.7 in females (p = 0.850) (Table 8a).  
 For FMT compared with an age-matched group of males, we found 25.0 % 
FMT to 20.5 % males of the same average age for cardiovascular diseases (p = 
0.282). For respiratory diseases, 15.0 % FMT to 11.4 % males (p = 0.403). For 
hormonal and metabolic diseases, 10.0 % FMT to 38.6 % males (p = 0.784). For 
gastroenterological diseases, 25.0 % FMT to 9.1 % males (p = 0.826). For urinary 
diseases, 5.0 % FMT to 11.4 % males (p = 0.001). For tumoral diseases, 5.0 % FMT 
to 2.3 % males (p < 0.001). For psychiatric disorders, 35.0 % FMT to 40.9 % males 
(p = 0.924). For immune mediated diseases, 5.0 % FMT to 4.6 % males (p = 0.005). 
In relation to smoking, we found 28.6 % of FMT smoked to 18.4 % male smokers (p = 
0.077). Regarding alcohol consumption, we found 19.1 % FMT to 59.1 %   males (p = 
0.107). BMI was 25.2 ± 4.8 in FMT vs. 27.5 ± 4.6 in males (p = 0.410). Number of 













 FMT-Female match FMT-Male match 
 Transsexuals DETECT  Transsexuals DETECT  
Diseases n % n % p n % n % p 
Cardiovascular 5 17.2 9 12.5 0.531 5 25.0 9 20.5 0.282
Respiratory 5 17.2 7 9.7 0.857 3 15.0 5 11.4 0.403
Neurological 1 3.5 10 13.9 0.001 0 0.0 4 9.1 NA 
Metabolic 5 17.2 34 47.2 0.369 2 10.0 17 38.6 0.784
Gastroenterological 7 24.1 9 12.5 0.298 5 25.0 4 9.1 0.826
Urinary 2 6.9 5 6.9 0.001 1 5.0 5 11.4 0.001
Tumoral 2 6.9 8 11.1 0.504 1 5.0 1 2.3 0.000
Psychiatric 10 34.5 28 38.9 0.656 7 35.0 18 40.9 0.924
Immune mediated 2 6.9 5 6.9 0.000 1 5.0 2 4.6 0.005
BMI (mean/SD) 25.4 4.8 24.9 5.2 0.302 25.2 4.8 27.5 4.6 0.410
 
Table 8a: Comorbidities in our patient sample in comparison with an age- and gender-matched control 
group from DETECT. FMT-female match and FMT-male match. NA: not applicable 
 
 
 For MFT compared with an age-matched group of males, we found 15.1 % 
MFT to 45.6 % males for cardiovascular diseases (p = 0.478). For respiratory 
diseases, 18.9 % MFT to 7.4 % males (p = 0.947). For neurological diseases, 18.9 % 
MFT to 14.1 % males (p = 0.704). For hormonal and metabolic diseases, 7.6 % MFT 
to 54.4 % males (p = 0.410). For gastroenterological diseases, 18.9 % MFT to 22.2% 
males  (p = 0.199). For urinary diseases, 9.4 % MFT to 9.4 % males (p = 0.688). For 
tumoral diseases 1.9 % MFT to 3.4 % males (p < 0.001). For psychiatric disorders, 
18.9 % MFT to 46.3 % males (p = 0.622). For immune mediated diseases, 11.3 % 
MFT to 4.0 % males (p = 0.094). In relation to smoking, we found 28.3 % of MFT 
smoked to 27.4 % male smokers (p = 0.839). Regarding alcohol consumption, we 
found 23.1 % MFT to 66.2 % males (p = 0.971). BMI was 27.8 ± 4.4 in MFT vs. 27.4 
± 4.6 in males (p = 0.004). Number of education years was 11.1 ± 2.5 in MFT vs. 
10.8 ± 2.3 in males (p = 0.145) (Table 8b). 
 Finally, for MFT compared with an age-matched group of females, we found 
14.3 % MFT to 35.0 % females for cardiovascular diseases (p = 0.899). For 
respiratory diseases, 17.9 % MFT to 6.9 % females (p = 0.331). For neurological 
diseases, 21.4 % MFT to 8.1 % females (p = 0.539). For hormonal and metabolic 
diseases, 7.1 % MFT to 48.1 % females (p = 0.930). For gastroenterological 
diseases, 17.9 % MFT to 18.1 % females (p = 0.332). For urinary diseases, 10.7 % 
MFT to 13.1 % females (p = 0.765). For tumoral diseases, 1.8 % MFT to 8.8 % 
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females (p < 0.001). For psychiatric disorders, 19.6 % MFT to 40.6 % females (p = 
0.133). For immune mediated diseases, 10.7 % MFT to 3.8 % females (p = 0.657). In 
relation to smoking, we found 26.8 % of MFT smoked to 21.4 % female smokers (p = 
0.237). Regarding alcohol consumption, we found 21.8 % MFT to 60.3 % females (p 
= 0.248). BMI was 25.2 ± 4.7 in MFT vs. 27.0 ± 6.1 in females (p = 0.728). Number of 
education years was 11.0 ± 2.4 in MFT vs. 10.4 ± 1.7 in females (p = 0.029) (Table 
8b).  
 
 MFT-Male match MFT-Female match 
 Transsexuals DETECT  Transsexuals DETECT  
Diseases n % n % p n % n % p 
Cardiovascular 8 15.1 68 45.6 0.478 8 14.3 56 35.0 0.899
Respiratory 10 18.9 11 7.4 0.947 10 17.9 11 6.9 0.331
Neurological 10 18.9 21 14.1 0.704 12 21.4 13 8.1 0.539
Hormonal-metabolic 4 7.6 81 54.4 0.410 4 7.1 77 48.1 0.930
Gastroenterological 10 18.9 33 22.2 0.199 10 17.9 29 18.1 0.332
Urinary 5 9.4 14 9.4 0.688 6 10.7 21 13.1 0.765
Tumoral 1 1.9 5 3.4 0.000 1 1.8 14 8.8 0.000
Psychiatric 10 18.9 69 46.3 0.622 11 19.6 65 40.6 0.133
Immune mediated 6 11.3 6 4.0 0.094 6 10.7 6 3.8 0.657
BMI (mean/SD) 27.8 4.4 27.4 4.6 0.004 25.2 4.7 27.0 6.1 0.728
 
Table 8b: Comorbidities in our patient sample in comparison with an age- and gender-matched control 
group from DETECT. MFT-male match and MFT-female match. 
 
 
5.6 Family history 
 
 In order to find out genetic and hereditary aspects of gender disorders, we 
included questions that addressed the family history for incidence of transsexuality 
and homosexuality. 
 Almost all patients (100% of FMT and 93.1 % of MFT) reported that there was 
nobody in their family with the same condition as them. Homosexuality in the family 
members of our patient sample had higher prevalence than transsexualism: 16.2% of 
FMT and 6.9% of MFT reported one or more members in their families being 
homosexual (p = 0.073).  
Regarding sibling numbers and birth order, we found that 78.4% of FMT and 
75.9% of MFT reported that they had brother/s and/or sister/s from the same parents; 
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35.1% and 48.3% of FMT and MFT respectively had brother/s; 54.0% and 50.0% 
respectively had sister/s. Approximately one-quarter, 27 % of FMT and 24.1% of 
MFT, were first born in relation to the rest of the siblings. Of the FMT, 16.2% had 
older brother/s, 32.4% had older sister/s, 21.6% had younger brother/s and 27.0% 
had younger sister/s. Of the MFT, 31 % had older brother/s, 25.9% had older sister/s, 
15.5% had younger brother/s and 22.4% had younger sister/s.  
 
 
5.7 Hormonal treatment: duration, regimes, effects and side effects  
 
 From the 95 patients in our patient sample, all the FMT received 
psychotherapy, 96.5 % of MFT also received psychotherapy. In FMT, 91.9 % patients 
and 96.5 % of MFT patients received HT. In FMT, 67.6 % patients and 70.7 % of 
MFT patients underwent a surgery for sex reassignment at the study time point. 
 The FMT of our patient sample were under hormonal treatment an average 
number of 4.9 ± 4.6 years. The MFT who took hormones at the time of our study took 
them for a similar period of years (6.5 ± 7.9) (p=0.483). 
 It is common for MFT as well as FMT to receive different regimes of treatment 
and to change the preparation or combination of drugs during the treatment. Tables 9 
and 10 show the percentage of patients in our sample who at some point of their 
treatment received the corresponding drug regimen. They are classified by way of 














FMT Treatment % 
        ▪ Transdermal testosterone  
                     - Testogel ® 23.5 
                     - Testim ® 5.9 
                     - Other 2.9 
        ▪ Intramuscular testosterone  
                     - Testoviron ® 61.8 
                     - Nebido ® 41.2 
                     - Other 20.6 
 
Table 9: Hormonal treatment regimes in FMT and percentage of patients 




                MFT Treatment % 
Estrogens alone  
        ▪ Transdermal estrogens  
                    - Gynokadin ®              37.5 
                    - Other 14.3 
        ▪ Oral estrogens  
                    - Estrifam ® 23.2 
                    - Other 14.3 
         ▪ Intramuscular estrogens % 
                   - Estradurin ® 12.5 
                   - Progynon ® 8.9 
                   - Other 3.6 
Cyproterone acetate (Androcur ®) + Estrogens  
          ▪ Androcur ® + transdermal estrogens  
                   - Androcur ® + Gynokadin ® 32.1 
          ▪ Androcur ® + oral estrogens % 
                   - Androcur ® + Estrifam ®  5.3 
                   - Androcur ® + other oral estrogen 1.8 
           ▪ Androcur ® + intramuscular estrogens % 
                   - Androcur ® + Estradurin ® 8.9 
                   - Androcur ® + other intramuscular estrogen 3.6 
 
Table 10: Hormonal treatment regimes in MFT and percentage of 




 Both FMT and MFT reported having experienced effects and side effects from 
the hormonal treatment.  
 Regarding positive effects for the FMT sample, 97.0 % reported changes in 
the voice (deeper voice), 94.1 % in fat distribution (masculine), 91.2 % in muscular 
mass (increased), 88.2 % in hair growth (increased hair growth, masculine hair 
distribution), 85.3 % in clitoris (increased size), 82.3 % in libido (increased), 76.5 % in 
menstruation (cessation), 38.2 % in breasts (reduction), 35.3 % in larynx (enlarged), 
26.5 % in fear status (decreased fears). Amongst the negative effects were; changes 
in weight in 85.3 % of the FMT, changes in mood in 67.6 % (variations, aggression), 
alopecia in 17.6 % and edema in 11.8 %. Other changes experienced by this group 
of patients were: 47.0 % in skin (rough, dry skin), 44.1 % in hair structure (dry, fine), 
32.3 % in sexual behaviour, 23.5 % in sexual practices, 8.8 % in bone, 5.9 % in 
nipples (Figure 4). In relation to the appearance of new diseases, we found that 67.7 
% of FMT reported acne during the treatment, 2.9 % reported cancer and 2.9 % a 
heart infarct. No FMT reported a stroke, diabetes mellitus, thromboembolism, 
galactorrhea or prolactinome under hormonal therapy (Table 11).  
Regarding positive effects in the group of MFT, 89.3 % experienced changes 
in breasts (enlarged), 85.7 % in fat distribution (feminine), 80.3 % in skin (softer, finer, 
more sensitive), 64.3 % in nipples (enlarged), 58.9 % in hair growth (decreased, less 
alopecia, feminine corporal hair distribution), 51.8 % in testicles (decreased size), 
39.3 % in hair structure (finer, softer), 33.9 % in erections (decreased), 19.6 % in the 
voice (feminine) (Figure 4). Amongst the negative effects reported were; in 67.8 % of 
patients changes in mood (depression, instability), in 66.1 % changes in libido 
(decreased), in 66.1 % changes in weight, in 62.5 % changes in muscular mass 
(decreased), in 33.9 % changes in fear status (increased), 14.2 % of the MFT 
patients reported galactorrhea and 5.3 % edema. Other changes reported were: 37.5 
% in sexual behaviour, 17.8 % in sexual practices, 10.7 % in larynx, 3.6 % in bones. 
In relation to the appearance of new diseases under the hormonal treatment, we 
observed that 7.1 % reported acne, 1.8 % a thromboembolic event, 1.8 % a prostatic 
hyperplasia and 1.8 % a heart infarct. No patient presented a stroke event, 
prolactinome or other cancer during therapy with sexual hormones (Table 11).  
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 Figure 4: Corporal and psychological changes in FMT and MFT under HT. 
 
 
       FMT (n = 34) MFT (n = 56) 
Diseases n % n % 
Acne 23 67.6 4 7.1 
Edema 4 11.8 3 5.3 
Galactorrhea 0 0 8 14.3 
Infarct 1 2.9 1 1.8 
Cancer 1 2.9 0 0 
Thromboembolism 0 0 1 1.8 
Diabetes mellitus 0 0 1 1.8 
Prostatic hyperplasia NA NA 1 1.8 
Prolactinome 0 0 0 0 
Stroke 0 0 0 0 
 
Table 11: Incidence of diseases under HT. Percentage and absolute number of FMT and MFT that 
reported each type of disease under cross-sex HT. NA: Not applicable. 
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In the group of FMT, 82.8 % presented an average weight increase and 20.7 
% reported a weight decrease at some point of the treatment. The mean increase 
was 10.8 ± 6.6 kg and the mean decrease was 12.7 ± 12.5 kg.  
In the group of MFT, 81.1% presented an average weight increase and 18.9 % 
reported a weight decrease at some point of the treatment. The mean increase was 
8.7 ± 9.8 kg and the mean decrease was 7.0 ± 4.0 kg. 
 
As reported before, at the time of the study, 25 out of the 37 FMT (67.6 %) and 
41 out of 58 MFT (70.7 %) had undergone surgery for sex reassignment. It is 
interesting to notice that 53.3 % of the FMT who had an ovariectomy and 57.1 % of 
those who had a hysterectomy (but not an ovariectomy) reported that some effects of 
the hormonal treatment were more marked after the surgery. A similar finding was 
observed in the MFT who underwent surgery to remove the testicles: 50 % of them 
reported more marked effects of the hormonal treatment after the surgical procedure.  
 
 
5.8 General evaluation of the perceived physical and psychological status  
 
 The level of satisfaction of the FMT and MFT patients with each of the 
treatment procedures was evaluated with a scale that scored from 0 to 100.  
 FMT reported a level of satisfaction of 77.2 ± 24.6 out of 100 with the 
psychotherapeutic procedures, 88.4 ± 13.3 with the HT and 77.6 ± 19.3 with the 
surgeries. MFT reported a 75.5 ± 23.4 out of 100 of satisfaction with psychotherapy 
(p=0.510), 75.6 ± 24.8 with HT (p=0.009) and 87.9 ± 14.8 with surgeries (p=0.016) 
(Table 12).  
 
      FMT (n = 37)         MFT (n = 58) p 
 Treatment Mean SD Mean SD  
 Psychotherapy 77.2 24.6 75.5 23.4 0.510 
 Hormone therapy  88.4 13.3 75.6 24.8 0.009 
 Surgery 77.6 19.3 87.9 14.8 0.016 
 
Table 12: Level of satisfaction of the transsexual patients with psychotherapeutic, hormonal and 




 In the final part of our questionnaire, we evaluated the overall corporal and 
psychological status of the patients in the different time points of the treatment 
phases (before diagnosis, during psychotherapy, under HT and after surgery).  
In the FMT, the average subjective corporal score before the medical 
diagnosis in our scale (0 to 100) was 66.2 ± 28.3. During psychotherapy, the score 
raised to 70.6 ± 24.1, under HT to 82.3 ± 16.3. Finally after surgery it was found to be 
worse, with 79.7 ± 13.9 (p=0.083) (Figure 5). The psychological score before the 
medical diagnosis in FMT was of 37.6 ± 24.4. This increased to 59.8 ± 23.6 during 
the psychotherapy and to 81.0 ± 14.9 under hormonal therapy. Finally after surgery, 
the patients achieved their highest level of psychological satisfaction with 92.4 ± 7.1 
(p<0.001) (Figure 6).  
 In the MFT the results were similar to the FMT for corporal score, and with an 
increasing tendency: before medical diagnosis the status was 70.3 ± 29.0. This value 
increased to 74.0 ± 22.4 during psychotherapy, to 75.8 ± 19.0 under HT and finally to 
82.0 ± 18.7 after surgery (p=0.018) (Figure 5). 
 The psychological score in the MFT before the medical diagnosis was low 
(39.0 ± 30.0), like the FMT. This increased to 58.9 ± 23.0 during the psychotherapy, 
then to 67.8 ± 19.5 under HT. This increasing tendency reached the highest level 
after surgery with 88.7 ± 13.0 (p<0.001) (Figure 6).   
 The difference between FMT and MFT regarding psychological status under 


















Figure 5: Progression curve for perceived corporal score 






















Figure 6: Progression curve for perceived psychological score  





























 The three main findings of our study were: 
 
 (I) There was not a high rate of transsexualism in the families of our patient 
sample, nor a high rate of medical intake or complications during their mother’s 
pregnancy. Nevertheless there was a higher rate of distocies than are observed in 
normal population. The prevalence of alterations in childhood and puberty in relation 
to gender and psychological disorders was also high. 
 
 (II) Apart from the wished effects of the HT, there was a high prevalence of 
side effects. Nevertheless the prevalence of lifelong comorbidities did not differ from 
a control gender- and age-matched population. 
 
(III) Transsexual patients were highly satisfied with all medical procedures and 
they reported an increasing level of satisfaction along all treatments. 
  
Ad (I) From the early clinical history, we observed that most of the patients did 
not report that their mothers took hormones or other medications during pregnancy. 
There were also not many alterations reported during pregnancy. In the case of the 
patients who reported complications during their birth, these complications did not 
differ from those observed in general society, although the prevalence was higher in 
our patient sample (around 10% of distocies reported in previous studies). That is 
why we cannot make any conclusive statement by using our questionnaire about the 
origin of the disease. We can only observe from the reported information that, already 
in childhood and puberty, an important proportion of patients reported problems with 
their sexual identity and also other psychiatric symptoms in some cases. 
 Most of the patients reported no gender identity disorders in the members of 
their families. Nevertheless the information obtained from the questionnaire was 
limited. Future studies to analyse genetic aspects would be interesting to find a 
hereditary pattern.  
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The fact that these patients did not present any remarkable abnormality in 
their chromosomes does not exclude that they might have slight abnormalities at a 
genetic level that could explain the origin of their disorder. That means that further 
studies would be helpful to determine what possible polymorphisms in the sexual 
chromosomes and autosomes of these patients could explain the phenomenon. 
Recently there have been reports in the literature of gene polymorphisms proposed 
to be related to transsexualism, like polymorphisms in the SRD5A2 gene [47]  and 
the CYP17 gene [48]. Polymorphisms in other sex steroid-related genes were 
proposed to be linked with male-to-female transsexualism [49, 50]. Other genes 
related to GID were, for instance, Xist [51], 21-hydroxylase and 3beta-hydroxysteroid 
dehydrogenase genes [52]. The H-Y antigen was also discussed as an associated 
factor to transsexualism [53]. 
 
  
 Ad (II) Almost all patients took psychotherapy and hormonal therapy at the 
time of the study. FMT were much younger when they started with medical treatment, 
therefore it is expected and also known from the clinical experience, that they will 
undergo all possible surgical interventions. This is something that does not always 
happen in MFT, since they are also older on average. The younger the patients are, 
the most likely that they will go through all the available medical procedures. 
 The HT regimes and different combinations of compounds are more diverse in 
MFT than in FMT. An interesting future topic of research would be to evaluate which 
combinations of drugs are more optimal and cause less side effects. Nevertheless in 
the group of MFT it is more difficult to evaluate the efficiency of the drug, due to the 
more heterogeneous range of possibilities and to the frequency of patients changing 
from one drug regime to another.  
 
 The hormonal regimens in presurgical transsexual people differ from one clinic 
to another [23]. For instance, in the Academic Hospital Vrije Universiteit in 
Amsterdam, they use testosterone esters 250 mg intramuscular every 2 weeks or 
testosterone undecanoate 160 mg/d in the treatment of FMT [24, 54]. In the 
Deparment of Obstretics and Gynecology at the National University of Singapore, 
they use testosterone esters 250 mg intramuscular every 3-4 weeks or testosterone 
cyclopentylpropionate 100 mg intramuscular every week [55]. 
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 Other examples of hormonal treatment regimens in MFT are that used in the 
Division of Endocrinology of the Mount Sinai School of Medicine (New York), where 
ethinyl estradiol 100 µg/d or conjugated equine estrogens 1.25-2.5 mg/d and 
medroxyprogesterone acetate 5-10 mg/d for 10 d/month during the first 6 months are 
used, with optional spirololactone 100-200 mg/d or cyproterone acetate [56].  In the 
Department of Endocrinology at the University of British Columbia (Vancouver), they 
use conjugated equine estrogens 0.625 g/d increased to 5 g/d for 3 of 4 weeks and 
spironolactone 100-200 mg/d gradually increased until testosterone is suppressed, 
and medroxyprogesterone 10 mg/d 2 weeks/month or continuously if needed [27].  
 
 Some positive and negative side effects of the HT that we observed in our 
patient sample were already reported in the literature. For instance, in FMT there are 
the changes in voice (deepened voice) [21], changes in menstruation (cessation of 
menses) [21, 29], changes in hair growth (hirsutism) [21], changes in clitoris (growth) 
[29], changes in larynx (laryngeal prominence) [57], changes in libido (increased 
libido and hypersexuality) [57], changes in breasts (breast atrophy) [58], changes in 
fat distribution (male fat distribution) [59], changes in muscles (increased muscle 
mass) [60], appearance of acne [24], changes in weight (weight increase) [25] and 
changes in mood (aggression) [57]. Other side effects reported in the literature which 
we did not observe in our group of FMT are; endometrial hyperplasia [33], sleep 
apnea [61] and ovarian cancer [34].  
 
 In MFT some effects and side effects already reported and that we also 
observed were: changes in breasts (gynecomastia) [62], changes in nipples 
(enlarged areola and nipple) [21], changes in skin (softened skin) [21], changes in 
testicles (reduced volume) [63], changes in erections (decreased spontaneous 
erections) [29], changes in libido (decreased libido) [21], redistribution of fat (female 
fat distribution) [57], changes in mood (calming effect) [57] and changes in hair 
growth (decreased hair growth) [64]. Amongst the negative effects are reported 
venous thrombosis [24] and changes in mood (depression) [25]. Other side effects 
reported in MFT which we did not observe were cholelithiasis [24], prolactinoma [2, 
36, 65], breast cancer [66] and prostatic carcinoma after orchiectomy [67]. 
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 We found that in both groups of transsexual patients, two of the most 
prevalent comorbidities were psychiatric and endocrine diseases, specifically 
depression and overweight. The diagnosis of transsexualism is a psychiatric 
diagnosis, therefore it makes sense that it appears to be related to other psychiatric 
disorders. On the other hand, the high prevalence of overweight disorders also 
makes sense in this frame, since one of the most prevalent side effects in patients 
under cross-sex HT was a marked weight increase. Nevertheless, the difference in 
the prevalence of comorbidities between FMT and MFT was only statistically 
significant for neurological problems: neurological diseases were more frequent in 
MFT than in FMT. It is also interesting to notice that FMT, in comparison with an age-
matched control group of females, had a significant lower prevalence of neurological 
diseases (including migraine, epilepsy or multiple sclerosis amongst others), but 
there was no difference in comparison with an age-matched group of males. In a 
previous study by Gourie-Devi et al., there was a lower prevalence of neurological 
disorders among men in comparison with women [68]. This allows us to speculate 
about an underlying common genetic predisposition that may link males to FMT, or a 
protective effect of testosterone and negative effect of estrogens in males and 
females in relation to this type of diseases.  
 
 In comparison with a population of females of the same average age from the 
DETECT cohort, we did not observe a statistically significant higher prevalence of 
lifetime diseases in our sample of FMT. We obtained the same result when we 
compared MFT with males of the same age. Moreover, neurological, urinary and 
immune mediated diseases were significantly more prevalent in females than in FMT. 
Nevertheless, when we compared FMT with males of the same age, we saw that in 
the latter tumoral and also immune mediated diseases were significantly less 
frequent. In MFT, we found that tumoral diseases were less frequent than in control 
males and females of the same age. A study by Parker et al. reported that the 
probability of a person developing cancer for the interval between birth and 59 years 
is higher in females than in males [69]. In this respect, we speculate about a 
protective effect of estrogens in relation to tumoral diseases only in men and a 
negative effect of testosterone only in females. The BMI did not differ for the FMT in 
relation to control females and males. We did not find differences between the BMI of 
MFT with control females, although in comparison with control males the BMI was 
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slightly higher. Nevertheless the average BMI value was, in all these cases, within 
the limit of normal weight and overweight. This data allows us to conclude that, 
despite the side effects of the HT, this therapy is not contraindicated, at least not in 
the short term. However, since in our study the patients were under HT for 5–6 years 
on average, further long-term studies should be conducted for a better evaluation.  
 
 Concerning toxic habits (tobacco and alcohol), we only found statistical 
differences between FMT and females: a significantly higher proportion of females 
smoke and drank alcohol in comparison with FMT. This reflects a healthier lifestyle in 
the FMT group. 
 
In a small percentage of the patients a congenital disease was known, 
adrenogenital syndrome. This condition caused the ambiguity of sexual development 
that may have led to the actual sexual identity disorder. Other cases of children with 
adrenogenital syndrome that also developed gender identity disorders have been 
reported in previous studies [70, 71]. In all these cases, the pre-/perinatal androgenic 
imbalances played a role in the origin of the disease. On the other hand, a high 
prevalence of polycystic ovaries was observed in FMT, also due to the 
hyperandrogenemia [32, 72]. 
 
 
 Ad (III) There are very few studies addressing the level of satisfaction and 
health in transsexual patients under medical treatment [73, 74]. Therefore we 
included some questions in our questionnaire to evaluate our sample of patients in 
this frame. We used a numerical scale to measure the subjective level of satisfaction 
of our patients in different respects. 
 In relation to the satisfaction of the patients with the medical procedures, we 
observed that, in general, the scored was always higher than 75 out of 100, which 
means an overall positive acceptance and well-being. This finding correlates with the 
fact that the corporal and psychological status before the medical diagnosis was in 
the lower ranges. 
 It is interesting also to see that FMT reported a higher level of satisfaction with 
HT than MFT. However, MFT were more satisfied with the surgeries than FMT. One 
of the possible explanations for this phenomenon could be the euphorizing effects of 
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testosterone in comparison with estrogens, which normally lead to a less positive 
psychological status. On the other hand, the fact that MFT were more satisfied with 
the surgery than FMT can be explained by taking into account that cross-gender 
surgeries in MFT have a more aesthetic and functional result than in FMT. 
 In relation to the corporal status, we saw that both FMT and MFT reported a 
high subjective level of satisfaction before diagnosis (more than 65 over 100 in our 
scale in average). This value increased on average in FMT, and statistically 
significantly in MFT, along all the medical procedures to the point after surgery. After 
having reported the side effects of the HT and also having taken into account all the 
common problems associated with surgery (possible infections, pain etc.), it is 
interesting to see that the subjective physical status improved significantly.  
 From the psychological point of view, the patients started on average from a 
lower level of well-being (not higher than 40 out of 100 in our scale in average). But 
in both MFT and FMT we observed a statistically significant increase through the 
different steps, showing a high subjective satisfaction after surgery. 
 
 
 Apart from the three mentioned main findings, we can also point out some 
other observations.   
 
 (i) FMT on average noticed their condition some years earlier than MFT, 
nevertheless both groups realized their gender disconformity on average the late 
childhood or at the beginning of puberty. A possible explanation for the fact that FMT 
were more precocious may be that girls reach puberty before boys, and this point in 
life seems to be the moment when they started questioning their gender condition. 
We confirm that transsexualism in most of the cases is noticed very early by the 
patients and it perturbs in a not unimportant way the life of the patient, their social 
interaction and further development. 
  
(ii) The average age of medical diagnosis was significantly much earlier in 
FMT than in MFT. FMT sought medical support in early adulthood, whereas MFT did 
so more than a decade later in life. This may be due to social reasons that kept the 
male patients away from making their condition public. Another explanation could be 
that MFT did not have such an urgent need to reveal themselves. 
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(iii) The age when FMT and MFT started living in the opposite gender role 
corresponds on average to the age of diagnosis. This might reflect that the patients 
waited until they had sought medical help to make their condition public. This is may 
be because they could be better accepted socially if it could be said that a doctor had 
diagnosed and treated their disease. On the other hand, FMT started living in the 
opposite gender role significantly much earlier than MFT. This showed again that 
FMT are more eager than MFT to change their condition. It seems that for FMT it was 
easier to reveal themselves, or that perhaps they had a greater need to do so. 
 Here the question arises if it would not be better for the patient to start with the 
treatment in the puberty, at least with the hormonal part, so that the body, starting 
from the early stages of sexual development, is changed in a more successful way. 
Since the patients come to treatment much later in life (especially the MFT), by then 
their body has already achieved the undesired masculine or feminine shape (bone 
structure, for instance), something that is very difficult to reverse.  
  
(iv) It is interesting to compare both groups of patients in terms of the people 
who first noticed their transsexual condition. In the case of FMT, the number of 
patients reporting that people close to them realized first their condition is very high, 
meaning their parents and friends. In comparison, nearly half of MFT report that 
nobody realized their condition. We noticed that it was easier to recognize the 
condition of FMT at an early stage in life for the people who lived close to them than 
for MFT. The reason may be that they were more eager to show their condition, 
whereas MFT tried to hide it more. This was perhaps due to the MFT not being so 
affected by their GID, or that they had a better sense of well-being and therefore did 
not need to manifest their condition so eagerly. 
 In previous studies by Zucker and collaborators on sibling sex ratio and birth 
order in children with GID, it was observed that boys with GID had a significant 
excess of brothers to sisters, and that they were born later relative to their brothers 
than they were relative to their sisters [75]. Girls with GID were significantly more 
likely to be early born than were controls [76].   
 
(v) We found no statistical difference between the percentage of FMT and 
MFT who were right-handed. In other studies where control females and males were 
used, it was observed that the transsexuals are less often right-handed for different 
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one-hand tasks than the control [77, 78], in other words, a higher proportion of 
transsexuals were left-handed in those studies. This supports the idea of an altered 
pattern of cerebral hemispheric organization in male and female transsexuals. 
  
(vi) Most FMT, as expected, were sexually oriented to women, and for nearly 
all of those who had a partnership it was with a woman. In contrast to what we would 
expect to find, there was much more diversity in the sexual inclination of MFT. Many 
of them were oriented to women or to both sexes. Also for most of those who had a 
partnership it was with a woman. On the other hand, many MFT were divorced or 
separated, most likely from a woman. Again we observed that MFT were not so 
straightforward with defining their tendencies as FMT, whereas FMT showed a 
clearer behaviour that was more in accordance with their masculine role. 
 
 (vii) Finally, we want to discuss also the possibility that we are facing two 
different phenomena: male-to-female transsexualism and female-to-male 
transsexualism. Some of the studies that support the biological hypothesis of causes 
of transsexualism are in favour of the idea that they are two different entities.  
Similarities between MFT and females were found, whereas there were less 
similarities between FMT and males [7, 79]. In our study we also found differences in 
the behaviour and development of MFT and FMT that support this idea. 
 
 
 For future projects, it would be interesting to conduct genetic studies to clarify 
the etiology of transsexualism and long-term clinical trials to evaluate the efficacy and 
side effects of the hormonal treatment.  
 
 
6.2 Methodology and patient sample 
 
 Of the 421 patients treated at the Endocrine Outpatient Clinic of the Max 
Planck Institute to whom the questionnaire was sent, 112 (26.6 %) were FMT and 
185 (43.9 %) were MFT (ratio MFT:FMT = 1.65). Of the 95 patients who participated 
in our study, the ratio was similar (MFT:FMT = 1.57). Here we observe a higher 
prevalence of MFT, which corresponds with the observations in other prevalence 
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studies [2]. In a study by Weitze and Osburg [46], the prevalence of FMT in relation 
to MFT in German society was found to be 2.5 times lower. Therefore we feel 
confident to assume our sample is a representative sample despite the fact that the 
response rate was low. 
 
One of the sources of error in this study is the “missing data” that occurs, for 
instance, from a no validation of the questionnaire, a false response or a 
misunderstanding of the questions (measurement bias). 
 An important percentage of patients to whom the questionnaire was sent did 
not respond (65.6 %). This may be due to their particular satisfaction or 
dissatisfaction about the medical support for their problem or due to their particular 
physical and psychological health state (selection bias). 
 There were two drop-outs in our study. One of them was due to the intersexual 
condition of one of the respondents, which is an exclusion criterion for the study. 
Another drop-out was because of the poor quality of the completed questionnaire. 
All the information for the study was obtained from this questionnaire. This 
means that some results are based on the patients’ own perceptions, although there 
is also some objective information. Nevertheless, it would also be interesting to 
complete this study with a review of the clinical history, where some parameters like 
laboratory data are measured in an objective way. 
 
 Age at the time of the study was significantly higher for the MFT than the FMT 
(more than 10 years on average). 
 The BMI was on average similar in FMT and MFT, and in both cases the value 
was within the limit between normal weight and overweight. That shows that even 
after the weight gain due to the hormonal treatment, the BMI remained still in the 
limits of normality. This fact excludes overweight as a risk factor for other metabolic 
diseases in these patients, at least at present. 
 
 We observed that the differences in school education level between MFT and 
FMT are not statistically significant. The average number of years of school was 
similar in both groups. The years of education did not differ in the FMT compared 
with an age-matched control group of males and females. Neither was there a 
difference between the number of years of education of the MFT matched with a 
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control group of males, although in comparison with females of the same age, we 
found that MFT had almost one year more of school education on average. 
The distribution of professional education in transsexual patients was similar to 
the rest of society, the majority of them having an intermediate level. The differences 
between MFT and FMT were statistically significant. A similar average proportion of 
FMT and MFT had a university degree. The largest part of the MFT had a 
Facharbeiterabschluss, whereas in the FMT the Berufsfachschuleabschluss was the 






























 We obtained three main findings from our study. 
 Regarding the etiology, we did not find a high rate of transsexualism in the 
family histories of our patient sample, nor did we find a high rate of intake of 
medication by the mothers or other complications during pregnancy. Nevertheless 
the prevalence of birth complications is higher than that reported by other studies in 
the normal population. Genetic studies are scarce up to now, but could provide more 
detailed knowledge on etiological aspects of transsexualism in the future. 
 
 Regarding adverse events and side effects of the HT in FMT and MFT, we 
found that many patients experienced a change in fat distribution (94.1% of FMT and 
85.7 % of MFT), weight (85.3 % of FMT and 66.1 % of MFT) and mood (67.6 % of 
FMT and 67.8 % of MFT) after starting hormonal therapy. Among the positive effects 
were increased muscular mass, masculine hair and fat distribution in FMT and 
enlargement of breasts, feminine fat distribution and softened skin in MFT. Negative 
effects included acne, alopecia and aggressivity in FMT, and decreased muscular 
mass, decreased libido and depression in MFT. Both FMT and MFT reported a 
considerable weight increase of 10.8 ± 6.6 kg in FMT and 8.7 ± 9.8 kg in MFT. 
Compared to age-matched control groups, we did not see higher prevalences of 
cardiovascular, endocrine or tumoral comorbidities in either FMT or MFT, matched to 
females and males in both groups. Therefore, we can conclude that the HT is safe, at 
least in the short term. Clinical trials are needed in order to evaluate the long-term 
consequences and to compare different treatment regimens head to head. 
 
 Finally, the transsexual patients in our sample were highly satisfied with all 
medical procedures. After very low scores for psychologically perceived health at the 
time of diagnosis, both FMT and MFT reported a continuous rise of psychological and 
physiological perceived satisfaction levels along the medical procedures. However, 
MFT were less satisfied with HT than FMT, while FMT were less satisfied than MFT 
with the surgical procedures.  
 In general, we can conclude that the therapy for transsexual patients provided 
by the medical system in southern Germany seems to be safe, with high levels of 
satisfaction reported by the patients.  
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Future studies revealing the etiology of transsexualism and clinical trials 




8. ABSTRACT/ SUMMARY 
 
Background: Transsexual patients are characterized by biologically normal 
genotypes and phenotypes which are combined with the conviction of belonging to 
the opposite sex. This conviction goes along with a desire for gender reassignment, 
which involves psychological, hormonal and surgical treatment. Limited data on the 
various aspects of transsexualism exists at present. 
 
Objective: This study aimed at evaluating etiological aspects of transsexualism, the 
efficacy and safety of the therapeutical procedures, and the role of patients’ 
satisfaction with the treatment. 
 
Methods: Questionnaires evaluating medical history, therapy side effects and therapy 
satisfaction, including standardized questionnaires on sleep and psychopathology 
have been developed and sent to all 439 transsexual patients that are currently 
treated at the Max-Planck-Institut of Psychiatry in Munich.  
 
Results: Ninety-five patients returned the questionnaire and their responses were 
analysed. Out of 95, 37 were FMT (average age 32 years; average age at diagnosis 
25 years) and 58 were MFT (average age 48 years; average age at diagnosis 39 
years). We found neither a high rate of gender identity disorders in the family 
histories of our patient sample nor a high rate of intake of medications by the mothers 
or other complications during pregnancy. Ninety-eight percent of the patients 
received psychotherapy, 94.7 % benefited from HT and 69.5 % had undergone 
surgery at the time of the study. The patients followed different HT regimes: FMT 
received testosterone in transdermal and/or intramuscular applications; MFT received 
transdermal, oral or intramuscular estrogens and cyproterone acetate in different 
combinations. Frequent side effects reported by FMT were acne, aggressivity and 
alopecia. In the group of MFT, depression, muscle mass decrease and libido 
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decrease were frequently found. Both groups experienced a significant weight 
increase following HT (mean increase 10.8 ± 6.6 kg in FMT and 8.7 ± 9.8 kg in MFT). 
Nevertheless, in comparison with an age-matched control group, we did not see 
higher prevalences of lifelong cardiovascular, endocrine or tumoral comorbidities. 
Both groups reported a high overall satisfaction with all therapies (MFT mean value 
for HT: 75.6 ± 24.8 on a scale of 0=worst to 100=best possible satisfaction. FMT 
mean value: 88.4 ± 13.3). 
 
Conclusion: We conclude that the therapy for transsexual patients seems to be safe 
with high levels of satisfaction reported by the patients. Further studies should be 
conducted in order to clarify the etiological aspects of transsexualism and to evaluate 






Hintergrund: Transsexuelle Menschen sind durch unauffällige Geno- und 
Phänotypen charakterisiert, verbunden mit der Überzeugung, dem 
gegengeschlechtlichen Geschlecht anzugehören. Diese Überzeugung geht mit dem 
Wunsch einer Geschlechtsumwandlung einher und diesbezügliche psychologische, 
hormonelle und chirurgische Behandlung zu erhalten. Es gibt bislang nur wenige 
Daten zu den verschiedenen Aspekten der Transsexualität. 
 
Objektive: Ziel des Projekts war es ätiologische Aspekte, Effektivität und 
Nebenwirkungen der geschlechtsangleichenden Therapie sowie grundsätzliche 
Therapiezufriedenheit von transsexuellen Patienten zu evaluieren.  
 
Methodik: Ein Fragebogen zu den Themenkomplexen medizinische Anamnese, 
Nebenwirkungen der Therapie und Therapiezufriedenheit, inklusive standardisierter 
Fragebögen zur Schlaf und Psychopathologie, wurde entwickelt und an alle 439 
transsexuellen Patienten gesandt, die derzeit im Max-Planck-Institut für Psychiatrie in 
München behandelt werden. 
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Ergebnisse: Fünfundneunzig Patienten sandten die Fragebögen zurück, die 
analysiert wurden. Von 95 Patienten, erfüllten 37 Patienten die Diagnose Frau-zu-
Mann Transsexualismus (FMT) (Durchschnittsalter 32 Jahre; Durchschnittsalter bei 
Diagnose 25 Jahre)  und 58 Patientinnen die Diagnose Mann-zu-Frau 
Transsexualität (MFT) (Durchschnittsalter 48 Jahre; Durchschnittsalter bei Diagnose 
39 Jahre). Wir sahen weder erhöhte Raten von Geschlechtsidentifikationsstörungen 
in den Familienanamnesen noch fanden wir erhöhte Raten von 
Medikamenteneinnahmen der Mütter oder andere Komplikationen während der 
Schwangerschaft. Achtundneunzig Prozent der Patienten erhielten Psychotherapie, 
94,7% der Patienten erhielten hormonelle Therapie (HT) und 69,5% hatten bereits 
chirurgische Eingriffe zum Studienzeitpunkt hinter sich. Die Patienten wurden mit 
unterschiedlichen hormonellen Behandlungskonzepten behandelt: FMT erhielten 
Testosteron in transdermaler Form und/oder intramuskular. MFT erhielten 
transdermal, oral oder intramuskular Östrogene und Cyproteron Acetat in 
verschiedenen Kombinationen. Häufige Nebenwirkungen bei FMT waren Akne, 
Aggressivität und Haarausfall. In der Gruppe der MFT fanden sich häufig 
Depressionen, Abnahme der Muskelmasse und der Libido. Beide Gruppen erfuhren 
eine signifikante Gewichtszunahme infolge der HT (durchschnittliche Zunahme um 
10.8 ± 6.6 kg in FMT und 8.7 ± 9.8 kg in MFT). Dennoch sahen wir im Vergleich zu 
einer alters-gematchte Kontrollgruppe keine erhöhten Lebenszeitprävalenzen für 
kardiovaskuläre, endokrine oder maligne Komorbiditäten. Beide Gruppen berichteten 
über eine hohe umfassende Zufriedenheit unter allen Therapien  (Durchschnittswert 
für HT bei MFT: 75.6 ± 24.8 auf einer Skala von 0 = schlechteste bis 100 = 
bestmögliche Zufriedenheit. Durchschnittswert FMT: 88.4 ± 13.3).  
  
Zusammenfassung: Wir schließen daraus, dass die Therapie von transsexuellen 
Patienten sicher zu sein scheint bei hoher Zufriedenheit der Patienten. Zukünftig sind 
klinische Studien wünschenswert, die ätiologische Aspekte des Phänomens 
Transsexualität klären können sowie die Langzeitkonsequenzen von HT im Vergleich 
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Fragebogenerhebung zu Therapieeffekten, -nebenwirkungen und -

















































































Größe: __________________________  
      
Gewicht: _________________________ 
 
Geschlecht:   
  
 Frau-zu-Mann-Transsexuell O 
 Mann-zu-Frau-Transsexuell O 
 Weder, noch    O Kommentar:________________________ 
 
 
Schulabschluss:    
 
 keiner     O 
 Hauptschule    O 
 Mittlere Reife   O 
 Fachoberschule   O  
 Abitur     O 
 Sonstiges:______________________________________________________ 
 
Gesamtanzahl an Schuljahren (ohne Berufsschule, Hochschule):________________  
 
 
Berufsausbildung:    
 
 keine     O 
 noch in Ausbildung   O 
 Facharbeiter-Abschluss  O 
 Berufsfachschulabschluss  O 
 Fachhochschulabschluss  O 






                                                                                                                                                    
Berufsstand:   
   
 Schüler/Student/in Ausbildung O 
 Wehr-/Zivildienst   O 
 berufstätig Vollzeit   O 
 berufstätig Teilzeit   O 
 berentet/pensioniert  O 
 arbeitssuchend   O 
 nicht berufstätig   O 
 
Erlernter Beruf: ____________________________________________________ 
 
Derzeitige Tätigkeit: ________________________________________________ 
 
 
FRAGEN ZUR ENTWICKLUNG/VORGESCHICHTE:  
 
Hat Ihre Mutter während der Schwangerschaft Hormone oder andere Medikamente 
eingenommen? 
 
 Nicht bekannt   O  
 Nein     O  
 Ja               O      
 
 Wenn ja, welche und aus welchem Grund_____________________________ 
  
Gab es Besonderheiten während der Schwangerschaft Ihrer Mutter (Krankheiten, 
Infektionen)?  
 
 Nicht bekannt   O  
 Nein     O  
 Ja     O      
 
 Wenn ja, inwiefern_______________________________________________ 
 
Gab es Besonderheiten bei Ihrer Geburt?  
 
 Nicht bekannt   O 
 Nein     O 
 Ja     O 
 
 Wenn ja, welche:________________________________________________ 
   
 Infektion     O 
 Mechanische Probleme   O 
 Abnormales Gewicht  O 
 Geburtszeitpunkt   O 
 66
Leiden oder litten Sie an einer angeborenen oder erblichen Erkrankung?  
 
 Nicht bekannt    O 
 Nein      O 
  Ja      O 
 
 Wenn ja, an welcher______________________________________________ 
 
 Adrenogenitales Syndrom (AGS)  O 
 Enzymatische Erkrankung   O 
 Fehlentwicklung der  
 Geschlechtsorgane    O     
 
Kennen Sie Ihr chromosomales Geschlecht? 
 
 Nein O 
 Ja O 
 
 Wenn ja:  
 
 Biologische Frau (46, XX)  O 
 Biologischer Mann (46, XY) O 
 Klinefelter-Syndrom (47, XXY) O 
 Turner-Syndrom (45, X0)  O 
 Anderes:_______________________________________________________ 
   
Gab es Besonderheiten in Ihrer Entwicklung während der Kindheit?   
 
 Nicht bekannt   O 
 Nein     O 
  Ja     O 
 
 Wenn ja, welche:________________________________________________ 
 
 Auffälligkeiten beim Wachstum    O 
 Auffälligkeiten beim Beginn des Laufens   O 
 Auffälligkeiten beim Beginn des Sprechens   O 
       
Gab es Besonderheiten in Ihrer Entwicklung während der Pubertät?   
 
 Nicht bekannt   O 
 Nein     O 
  Ja     O 
 
 Wenn ja, welche:________________________________________________ 
 
Alter bei erster Regelblutung (wenn zutreffend) 
 




Hatten Sie normale weitere Regelblutungen (wenn zutreffend)? 
    
 Ja O 
 Nein O 
 
 Wenn nein, welche Besonderheiten:_________________________________ 
 
Haben Sie leibliche Kinder?   
    
 Nein O 
 Ja O 
 
 Wenn ja: 
  
 Anzahl und Alter der Söhne:________________________________________ 
 
 Anzahl und Alter der Töchter:_______________________________________ 
 
Gab es Besonderheiten in Ihrer Schwangerschaft (wenn zutreffend)? 
   
 Nein O 
 Ja O 
 
 Wenn ja, welche (inklusive Fehlgeburt und Abtreibungen):________________ 
 
Händigkeit (Schreibhand):    
 
 rechts  O 
 links   O 
 beidhändig  O 
 
In welchem Alter haben Sie Ihre Transsexualität das erste Mal bemerkt?   
 
 Im ____________Lebensjahr 
 
















In welchem Alter wurde die Transsexualität von ärztlicher Seite diagnostiziert?  
 
 Im ____________Lebensjahr 
 
Seit welchem Alter leben Sie in der gegengeschlechtlichen Geschlechtsrolle?  
 
 Seit ____________Lebensjahr 
 
Hat eine Namensänderung stattgefunden? 
 
 Nein O 
 Ja O 
 
 Wenn ja, wann__________ 
 
Hat eine Personenstandsänderung stattgefunden? 
 
 Nein O 
 Ja O 
 
 Wenn ja, wann__________ 
 
Fühlen Sie sich eher zu Männern oder Frauen hingezogen?          
 
 eher zu Männern    O 
 eher zu Frauen    O 
 zu beiden Geschlechtern   O 
 unentschieden    O  
 
Leben Sie in einer festen Partnerschaft?   
 
 Nein O   
 Ja O    
 
 Wenn, ja: 
 Mit Mann     O  
 Mit Frau     O    
 Mit Mann-zu-Frau Transsexueller O 
 Mit Frau-zu-Mann Transsexuellem O 
 
Wie ist die sexuelle Orientierung Ihres Partners/Ihrer Partnerin? 
 
 eher zu Männern    O 
 eher zu Frauen    O 
 zu beiden Geschlechtern   O 
 Mann-zu-Frau Transsexualität  O 






Wie ist Ihr Familienstand?   
 
 ledig      O 
 verheiratet mit Mann   O 
 verheiratet mit Frau    O 
 geschieden/getrennt lebend  O 
 verwitwet     O 





Leiden Sie derzeit oder litten Sie in der Vergangenheit an einer körperlichen oder 
psychischen Krankheit? 
 
 Nein O 
 Ja O 
   
 Wenn ja, bitte genauere Angaben: 
 
 Erkrankungen des Herz-Kreislauf-Systems  O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
 
 Erkrankungen des Atemtrakts     O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
 
 Erkrankungen des Gehirns oder Nervensystems O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 




 Hormonelle Erkrankungen     O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
 
 Erkrankungen der sexuellen Organe    O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
 
 Erkrankungen des Magen-Darm-Trakts   O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
 
 Erkrankungen der Nieren und Harnwege   O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
 
 Tumorerkrankungen     O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 







 Psychiatrische Erkrankungen    O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
 
 Erkrankungen des Inmunsystems    O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
 
 Erkrankungen des Blutes (z. B. Gerinnungsstörung) O 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
 
 Erkrankungen des Knochenapparats    O 
 (z.B. Frakturen, Osteoporose) 
 Welche:_________________________________ 
 Seit wann:_______________________________ 
 Therapie:________________________________ 
 Derzeit:  Nein O       Ja O 
   
Welche Medikation nehmen Sie derzeit ein? 
 
 1. ____________________________________________________________ 
 
 2. ____________________________________________________________ 
 
 3. ____________________________________________________________ 
 
 4. ____________________________________________________________ 
 
 5. ____________________________________________________________ 
 







 Nein  O 
 Ja  O 
 Aufgehört O Datum:_________ 
 
 Kommentar: __________________________________________________
    
Trinken Sie regelmäßig Alkohol?  
 
 Nein  O 
 Ja  O 
 Aufgehört O Datum:_________ 
 
 Kommentar: __________________________________________________ 
 
Treiben Sie mehr als 2 x 30 Minuten pro Woche Sport? 
 
 Nein  O 
 Ja  O 
 






Gibt es in Ihrer Familie Personen, bei denen eine Transsexualität vorliegt? 
 
 Nein  O 
 Ja  O 
 
 Wenn ja, bei wem:_______________________________________________ 
 
Gibt es in Ihrer Familie Personen, bei denen eine Homosexualität vorliegt? 
 
 Nein O 
 Ja O 
 
 Wenn ja, bei wem:_______________________________________________ 
 
Haben Sie Geschwister?    
 
 Nein O  




Wenn ja, bitte Kommentar (Anzahl und Alter von Brüdern und Schwestern mit 









          
 
An welcher Stelle stehen Sie in der Geschwisterreihe? 
 
 Erstgeborener/e    O 
 Zweitgeborener/e  O 
 Drittgeborener/e  O  
 Letztgeborener/e   O 
 Andere Reihenfolge O  Welche?_____________________________________ 
 
Gab es oder gibt es schwere oder chronische Erkrankungen in Ihrer Familie?  
 
 Nicht bekannt   O 
 Nein     O 
 Ja     O 
 














FRAGEN ZUR THERAPIE: 
 
Wer behandelt Sie? (Mehrfachnennungen möglich) 
 
 Hausarzt/Hausärztin O 
 Endokrinologe/in   O 
 Urologe/in    O 
 Gynäkologe/in   O 
 Psychiater/in   O 
 Psychotherapeut/in  O 





Erhalten Sie oder haben Sie eine Psychotherapie erhalten? 
  
 Nein    O 
 Ja    O 
 
 Wenn ja: 
    
 vor dem Alltagstest  O 
 während des Alltagstests O 
 im Anschluß an die OP O     
 
  Anzahl der Sitzungen insgesamt: ______ 
 
Welche Art von Psychotherapie erhalten Sie oder haben Sie erhalten?  
       
 Verhaltenstherapie      O 
 Tiefenpsychologische/analytische Psychotherapie O 
 Nicht bekannt       O 




Was war Ihre Motivation für die Psychotherapie? 
  
 Gutachten   O 
 eigene Motivation  O 
 Andere:________________________________________________________
         
Hat Ihr/e Therapeut/in Erfahrung mit der Behandlung von transsexuellen Patienten?  
 
 Nicht bekannt    O 
 Nein     O 
 Ja     O 
 75











Bitte markieren Sie: 0= überhaupt nicht zufrieden, 100= total zufrieden). 
 
Beispiel: „Ich bin 75% zufrieden“ 
----------------------------------------------------------------------------------------------------X---------------------------------- 
0 10 20 30 40 50 60 70 80 90 100 
 
 Bitte hier ankreuzen: 
 
_______________________________________________________ 
   
  0        10 20 30 40 50 60 70 80 90 100 
 
 
Haben oder hatten Sie Probleme bei der Psychotherapie?  
 
 Eher nein O 
 Eher ja O 
 
 Wenn ja, welche_________________________________________________ 









Erhalten Sie eine gegengeschlechtliche hormonelle Therapie? 
  
 Nein O 
 Ja O 
 











 von__________  bis__________ 
   
 b)_______________________________________________________ 
 








 vom__________  bis__________ 
  
Sind Sie zufrieden mit der hormonellen Therapie?  
(0= überhaupt nicht zufrieden, 100= total zufrieden) 
  
 Bitte hier ankreuzen: 
 
_______________________________________________________ 
   
  0        10 20 30 40 50 60 70 80 90 100 
 
Sind Sie zufrieden mit dem Zeitpunkt des Beginns der hormonellen Therapie? 
 
 Nein O 
 Ja O 
 




Haben Sie Wirkungen, Nebenwirkungen bzw. Veränderungen durch die hormonelle 
Therapie bemerkt?  
 
 Nein O 
 Ja O 
 
Wenn ja, bitte Zutreffendes ankreuzen (mit der Bitte um nähere Angaben): 
 
Veränderungen der Haut       O 
Wenn ja, inwiefern_____________________________________________________ 
  
Veränderungen der Haarstruktur      O 
Wenn ja, inwiefern_____________________________________________________ 
 77
Veränderungen des Haarwuchses     O 
Wenn ja, inwiefern_____________________________________________________ 
 
Akne/Pickel/Pusteln         O 
Wenn ja, inwiefern_____________________________________________________ 
Veränderungen der Hodengröße (wenn zutreffend)   O  
Wenn ja, inwiefern_____________________________________________________ 
Veränderungen der Klitoris (wenn zutreffend)    O  
Wenn ja, inwiefern_____________________________________________________ 
  
Neu aufgetretene Krebserkrankungen     O 
Wenn ja, welche (mit Erstdiagnosedatum)__________________________________ 
 
Veränderungen/Ausbleiben der Menstruation (wenn zutreffend) O 
Wenn ja, inwiefern_____________________________________________________ 
Prostatahyperplasie (wenn zutreffend)     O  
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderungen der sexuellen Lust/Libido    O 
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderungen des Sexualverhaltens     O 
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderung der Sexualpraktiken     O 
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderung spontaner Erektionen (wenn zutreffend)  O 
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderungen des Brustumfangs     O  
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderungen der Brustwarzengröße     O  
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderungen der Stimmung      O 
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderungen der Ängstlichkeit      O 
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderungen von Leber, Gallenblase, Gallenwegen   O 
Wenn ja, inwiefern_____________________________________________________ 
 
Auftreten eines Herzinfarktes      O  
Wenn ja, wann:_______________________________________________________ 
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Auftreten eines Schlaganfalls      O  
Wenn ja, wann:_______________________________________________________ 
 
Auftreten eines Diabetes mellitus (Blutzuckererkrankung)  O 
Wenn ja, wann:_______________________________________________________ 
 
Auftreten einer Thrombose/Embolie     O  
Wenn ja, wann:_______________________________________________________ 
  
Veränderung der Stimme       O 
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderungen des Kehlkopfes      O  
Wenn ja, inwiefern_____________________________________________________ 
 
Veränderungen des Körpergewichts      O 
Wenn ja, inwiefern_____________________________________________________ 
 
 Gewichtzunahme um_____ kg 
 Gewichtabnahme um_____ kg 
 
Veränderung der Fettverteilung      O 
Wenn ja,  
männlicher   O                            
weiblicher   O          männlich    weiblich 
      
                                                 
Veränderungen der Muskelmasse/Muskelstärke   O  
Wenn ja, inwiefern_____________________________________________________ 
 
Treiben Sie Sport oder machen Sie Krafttraining unter der hormonellen Therapie? 
Nein    O 
Ja    O 
 
Veränderung der Knochendichte      O 
Wenn ja, inwiefern_____________________________________________________ 
 
Auftreten von Wassereinlagerungen (Ödemen)   O  
Wenn ja, wann:_______________________________________________________ 
 
Auftreten von Milchfluß aus der Brust     O  
Wenn ja, wann:_______________________________________________________ 
 
Prolaktinom         O 
Wenn ja, wann:_______________________________________________________ 
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Haben Sie bemerkt, dass einige der oben genannten Veränderungen ausgeprägter 
nach der geschlechtsangleichenden-OP (wenn zutreffend) waren? 
   
 Nein O 
 Ja O  
 
 Wenn  ja, welche________________________________________________ 
 
Haben oder hatten Sie andere Probleme mit der hormonellen Therapie?  
 
 Nein O 
 Ja O 
 
 Wenn ja, welche_________________________________________________ 
 














Wurden Sie geschlechtsangleichend operiert? 
 
 Nein O  
 Ja  O         
 
 Wenn ja, welche Operationen wurden durchgeführt (mit Datum)? 
 
 1.Art der OP/Datum:______________________________________________ 
 
 2.Art der OP/Datum:______________________________________________ 
 
 3.Art der OP/Datum:______________________________________________ 
 







Sind Sie zufrieden mit der operativen Therapie?  
(0= überhaupt nicht zufrieden, 100= total zufrieden) 
  
 Bitte hier ankreuzen: 
 
_______________________________________________________ 
   
  0        10 20 30 40 50 60 70 80 90 100 
 
Gab es Probleme/Nebenwirkungen der operativen Therapie?       
                
 eher nein O  
 eher ja O                    
 
 Wenn ja, inwiefern_______________________________________________ 
 
 
















Erhalten oder haben Sie jemals eine Epilationstherapie erhalten? 
 
 Nein  O 
 Ja  O 
 
 Wenn ja, wann und wie oft:_________________________________________ 
 
Wie sehr sind bzw. waren Sie zufrieden mit der Epilationstherapie? 
(0= überhaupt nicht zufrieden, 100= total zufrieden) 
 
 Bitte hier ankreuzen: 
 
_______________________________________________________ 
   





Haben oder hatten Sie jemals eine logopädische Therapie? 
 
 Nein  O 
 Ja  O 
 
 Wenn ja, wann und wie oft:________________________________________ 
 
Wie sehr sind bzw. waren Sie zufrieden mit der Logotherapie? 
(0= überhaupt nicht zufrieden, 100= total zufrieden) 
 
 Bitte hier ankreuzen: 
 
________________________________________________________ 
   
  0       10        20 30 40 50 60 70 80 90 100 
  
Hatten Sie eine Kehlkopf-OP? 
 
 Nein  O 
 Ja  O 
 
 Wenn ja, wann:_________________________________________________ 
 
Wie sehr sind bzw. waren Sie zufrieden mit der Kehlkopf-OP? 
(0= überhaupt nicht zufrieden, 100= total zufrieden) 
 
 Bitte hier ankreuzen: 
 
________________________________________________________ 
   







Wie würden Sie Ihren körperlichen Gesundheitszustand vor der Erstdiagnose und 
Beginn der psychiatrisch/psychotherapeutischen Behandlung beschreiben? 
(0= schlechtester denkbarer Zustand, 100=bester denkbarer Zustand) 
 
 
 Bitte hier ankreuzen: 
 
 _______________________________________________________ 
   





Wie würden Sie Ihren körperlichen Gesundheitszustand während der 
psychiatrisch/psychotherapeutischen Behandlung beschreiben (wenn zutreffend)? 
(0= schlechtester denkbarer Zustand, 100=bester denkbarer Zustand) 
 
 
 Bitte hier ankreuzen: 
 
________________________________________________________ 
   
  0        10       20 30 40 50 60 70 80 90 100 
 
 
Wie würden Sie Ihren körperlichen Gesundheitszustand während der 
endokrinologischen Behandlung beschreiben (wenn zutreffend)? 
(0= schlechtester denkbarer Zustand, 100=bester denkbarer Zustand) 
 
 
 Bitte hier ankreuzen: 
 
________________________________________________________ 
   
  0        10 20 30 40 50 60 70 80 90 100 
 
 
Wie würden Sie Ihren körperlichen Gesundheitszustand nach der operativen 
Behandlung beschreiben (wenn zutreffend)? 
(0= schlechtester denkbarer Zustand, 100=bester denkbarer Zustand) 
 
 
 Bitte hier ankreuzen: 
 
________________________________________________________ 
   
  0        10       20 30 40 50 60 70 80 90 100 
 
 
Wie würden Sie Ihren psychischen Gesundheitszustand vor der Erstdiagnose und 
Beginn der psychiatrisch/psychotherapeutischen Behandlung beschreiben? 
(0= schlechtester denkbarer Zustand, 100=bester denkbarer Zustand) 
 
 Bitte hier ankreuzen: 
 
________________________________________________________ 
   








Wie würden Sie Ihren psychischen Gesundheitszustand während der 
psychiatrisch/psychotherapeutischen Behandlung beschreiben (wenn zutreffend)? 
(0= schlechtester denkbarer Zustand, 100=bester denkbarer Zustand) 
 
 
 Bitte hier ankreuzen: 
 
_________________________________________________________ 
   
  0        10       20 30 40 50 60 70 80 90 100 
 
 
Wie würden Sie Ihren psychischen Gesundheitszustand während der 
endokrinologischen Behandlung beschreiben (wenn zutreffend)? 
(0= schlechtester denkbarer Zustand, 100=bester denkbarer Zustand) 
 
 
 Bitte hier ankreuzen: 
 
________________________________________________________ 
   
  0        10       20 30 40 50 60 70 80 90 100 
 
 
Wie würden Sie Ihren psychischen Gesundheitszustand nach der operativen 
Behandlung beschreiben (wenn zutreffend)? 
(0= schlechtester denkbarer Zustand, 100=bester denkbarer Zustand) 
 
 
 Bitte hier ankreuzen: 
 
________________________________________________________ 
   










Schlafqualitäts-Fragebogen (PSQI)  
 
 
1. Wann sind Sie während der letzten vier Wo-
chen gewöhnlich abends zu Bett gegangen? 
 
 
2. Wie lange hat es während der letzten vier 
Wochen gewöhnlich gedauert, bis Sie 
nachts eingeschlafen sind? 
 
3. Wann sind Sie während der letzten vier Wo-
chen gewöhnlich morgens aufgestanden? 
 
 
4. Wieviele Stunden haben Sie während der 
letzten vier Wochen pro Nacht tatsächlich 
geschlafen? 
 (Das muß nicht mit der Anzahl der Stunden, die Sie 




5. Wie oft haben Sie während der letzten vier Wochen schlecht geschlafen, ... 
 
a) ... weil Sie nicht innerhalb von 30 Minuten ein-






b) ... weil Sie mitten in der Nacht oder früh mor-














 Die folgenden Fragen beziehen sich auf Ihre üblichen Schlafgewohnheiten und zwar  nur 
während der letzten vier Wochen. Ihre Antworten sollten möglichst genau sein und sich auf 
die Mehrzahl der Tage und Nächte während der letzten vier Wochen beziehen. Bean twor-
ten Sie bitte alle Fragen. 
 
 
   übliche Uhrzeit:  
 
 
   in Minuten: 
 
 
   übliche Uhrzeit:  
 
 





 Kreuzen Sie bitte für jede der folgenden Fragen die für Sie zutreffende Antwort an. Bean t-
worten Sie bitte alle Fragen. 
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 















































6. Wie würden Sie insgesamt die Qualität Ihres 







    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro  Woche 
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    Und wie oft während des letzten Monats konnten 
    Sie aus diesem Grund schlecht schlafen?  
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 








    m  Sehr gut 
    m  Ziemlich gut 
    m  Ziemlich schlecht 
    m  Sehr schlecht 
 
 7. Wie oft haben Sie während der letzten vier 
Wochen Schlafmittel eingenommen (vom 





8. Wie oft hatten Sie während der letzten vier 
Wochen Schwierigkeiten wachzubleiben, 





9. Hatten Sie während der letzten vier Wochen 
Probleme, mit genügend Schwung die übli-



























c) Zucken oder ruckartige Bewegungen der Beine 







    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Keine Probleme 
    m  Kaum Probleme 
    m  Etwas Probleme 
    m  Große Probleme 
 
 
    m  Ja 
    m  Ja, aber ein Partner/Mitbewohner schläft in einem anderen Zimmer  
    m  Nein, der Partner schläft im selben Zimmer, aber nicht im selben Bett  
    m  Nein, der Partner schläft im selben Bett  
 
 
 Falls Sie einen Mitbewohner / Partner haben, fragen Sie sie/ihn bitte, ob und wie oft er/sie bei Ihnen 
folgendes bemerkt hat. 
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 
    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 
 d) Nächtliche Phasen von Verwirrung oder Desori-




















    m  Während der letzten vier Wochen gar nicht  
    m  Weniger als einmal pro Woche  
    m  Einmal oder zweimal pro Woche 
    m  Dreimal oder häufiger pro Woche  
 







Körpergröße: ..............          Gewicht:...................  
 
Beruf:           ¦ Rentner(in) 
           ¦ selbständig 
 ¦ Schüler/Student(in)  ¦ Angestellte(r) 
 ¦ Arbeiter(in)   ¦ arbeitslos/ Hausfrau(mann) 
 
 
   Alter:    ____ Jahre 
 
   Geschlecht:  ¦ weiblich 





Die folgende Frage bezieht sich auf Ihr normales Alltagsleben in der letzten Zeit:
Für wie wahrscheinlich halten Sie es, daß Sie in einer der folgenden 
Situationen einnicken oder einschlafen würden, - sich also nicht  nur 
müde fühlen?
Auch wenn Sie in der letzten Zeit einige dieser Situationen nicht erlebt haben, versuchen 
Sie sich trotzdem vorzustellen, wie sich diese Situationen auf Sie ausgewirkt hätten.
Benutzen Sie bitte die folgende Skala, um für  jede Situation eine möglichst genaue 
Einschätzung vorzunehmen und kreuzen Sie die entsprechende Zahl an:
0 = würde niemals einnicken
1 = geringe Wahrscheinlichkeit einzunicken
2 = mittlere Wahrscheinlichkeit einzunicken
3 = hohe Wahrscheinlichkeit einzunicken
Situation Wahrscheinlichkeit 
einzunicken
Im Sitzen lesend    
Beim Fernsehen    
Wenn Sie passiv (als Zuhörer) in der Öffentlichkeit sitzen 
(z.B. im Theater oder bei einem Vortrag)    
Als Beifahrer im Auto während einer einstündigen Fahrt 
ohne Pause    
Wenn Sie sich am Nachmittag hingelegt haben, um 
auszuruhen    
Wenn Sie sitzen und sich mit jemand unterhalten    
Wenn Sie nach dem Mittagessen (ohne Alkohol) ruhig 
dasitzen    
Wenn Sie als Fahrer eines Autos verkehrsbedingt einige 
Minuten halten müssen    
Bitte nicht ausfüllen
Summe
FRAGEBOGEN ZUR ERFASSUNG VON RUHELOSEN BEINEN
Bitte geben Sie an, ob die folgenden Aussagen auf Sie zutreffen:
1. Kommt es vor, dass Sie Missempfindungen (z.B. Ziehen, Stechen, Kribbeln, 
Schmerzen) oder ein schwer zu beschreibendes, unangenehmes Gefühl in den 





















5. Können Ihre Beschwerden durch Bewegung (z.B. Bewegen der Beine, Umhergehen) 













8. Kommt es vor, dass Ihre Beine während des Schlafes oder tagsüber in Ruhesituationen 





9. Treten oder traten früher Ihre Beschwerden nicht regelmäßig auf, sondern gibt/gab es 





10. Gibt es in Ihrer Familie noch andere Personen, die ähnliche Beschwerden haben?
       





Bitte beantworten Sie die folgenden Fragen NUR, wenn die oben genannten Missempfindungen in 
den Beinen oder der Drang, die Beine zu bewegen, bei Ihnen jemals aufgetreten sind:
11.Wie häufig treten die Beschwerden auf?
 Vor ca. ______ Jahren, jetzt nicht mehr
 Weniger als einmal pro Jahr
 Ein- oder mehrmals pro Jahr
 Ein- oder mehrmals pro Monat
 Ein- oder mehrmals pro Woche
 Jede oder fast jede Nacht
12. Wann sind diese Symptome zum ersten Mal aufgetreten:       im Alter von ______ Jahren
13. Wie schwer sind diese Symptome insgesamt?
 sehr gering   gering        mäßig     stark       sehr stark
14. Wie stark wirken sich die Symptome insgesamt auf Ihre Alltagsaktivitäten aus, etwa auf Ihr 
Familienleben, Ihr häusliches Umfeld, Ihre Kontakte zu Freunden und Bekannten oder Ihre 
berufliche Arbeit?
 gar nicht       gering        mäßig     stark       sehr stark
FRAGEBOGEN ZUR ERFASSUNG VON SCHLAFBEZOGENEN 
ATMUNGSSTÖRUNGEN
Hat sich Ihr Gewicht verändert?  zugenommen
 abgenommen
 unverändert
Schnarchen Sie?  ja
 nein
 weiß nicht
Wie laut schnarchen Sie?  so laut wie Atmen
 so laut wie Sprechen
 lauter als Sprechen
 sehr laut
Wie häufig schnarchen Sie?  fast jeden Tag
 3 – 4 mal pro Woche
 1 – 2 mal pro Woche
 1 – 2 mal pro Monat
 nie oder fast nie
Stört Ihr Schnarchen andere Personen?  ja
 nein
Wie häufig fielen bei Ihnen Atempausen auf?  fast jeden Tag
 3 – 4 mal pro Woche
 1 – 2 mal pro Woche
 1 – 2 mal pro Monat
 nie oder fast nie
Sind Sie nach dem Erwachen müde?  fast jeden Tag
 3 – 4 mal pro Woche
 1 – 2 mal pro Woche
 1 – 2 mal pro Monat
 nie oder fast nie
Sind Sie während des Tages müde?  fast jeden Tag
 3 – 4 mal pro Woche
 1 – 2 mal pro Woche
 1 – 2 mal pro Monat
 nie oder fast nie
Sind Sie schon einmal beim Autofahren eingeschlafen?  ja
 nein
Haben Sie einen erhöhten Blutdruck?  ja
 nein
 weiß nicht
 Münchner Parasomnie Screening (MuPS)
Dieser  Fragebogen  wurde  entwickelt,  um  die  Häufigkeit  bestimmter 
nächtlicher Verhaltensweisen zu erfassen.
Was Sie bei dem folgenden Fragebogen beachten sollten
1. Bitte vergessen Sie nicht, die dick umrandete, dunklere Spalte mit der Aufschrift 
„Woher wissen Sie, dass dieses Verhalten bei Ihnen auftritt?“ auszufüllen. Sie 
trifft immer dann zu, wenn das beschriebene Verhalten von Ihnen und/oder von 
anderen (z.B. Familie oder Zimmernachbar) tatsächlich beobachtet wurde.
2. Nutzen Sie bitte die Spalte „Bemerkungen“ für genauere Angaben:
wenn Häufigkeitsangaben wie „selten/manchmal/oft“ Ihnen schwer fallen, da 
das beschriebene Verhalten in extrem unregelmäßigen Intervallen auftritt
wenn die Beschreibung des nächtlichen Verhaltens nicht ganz auf das Ihrige 
zutrifft, jedoch ähnlich ist 
wenn Sie eine Vermutung haben, wieso dieses Verhalten auftreten könnte 
(z.B. bei nächtlichen Wadenkrämpfen könnte die Ursache Magnesium-Mangel 
sein)
3. Falls ein aufgelistetes Verhalten bei Ihnen vor längerer Zeit auftrat, jedoch nicht 
regelmäßig oder nicht zur Zeit auftritt, nutzen Sie bitte die Spalte „Wurde vor Jahren 
beobachtet, jetzt jedoch nicht mehr“.
Angaben zum allgemeinen Schlafverhalten




2. Haben Sie Schlafstörungen?
 Nein
 Ja, und zwar______________________________________________________________
Münchner Parasomnie Screening
Max Planck Institut für Psychiatrie
Bereich Schlafmedizin
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Wie häufig treten folgende 































Woher wissen Sie, 
dass dieses Verhalten 
bei Ihnen auftritt?
Bemerkungen
Einschlafzuckungen in den Beinen oder Körper, 
die plötzlich und unabsichtlich auftreten, oft 
mit einem Gefühl des Fallens verbunden

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Rhythmische und schnelle Beinbewegungen 
während des Einschlafens oder Halbschlafes, 
die auch willentlich auftreten können

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Rhythmische und wiederholte Bewegungen des 
Kopfes oder des Körpers beim Einschlafen oder 
während nächtlicher Wachphasen z.B. sich in 
den Schlaf wiegen, wippen oder schaukeln

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Die Wahrnehmung eines lauten Knalles, eines 
Knall-ähnlichen Geräusches (z.B. 
Türenknallen) oder das Gefühl einer „Explosion 
im Kopf“ beim Einschlafen oder Aufwachen

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Täuschungen des Hörens oder des Sehens , die 
das Einschlafen oder Aufwachen quälend oder 
bedrohlich begleiten (z.B. Geräusche oder 
Stimmen hören, Personen oder Dinge sehen, die 
nicht im Raum sind)

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Wiederholtes, unwillkürliches Zucken der 
Beine oder Treten während des Schlafes 
(kann nur durch Dritte beobachtet werden)

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
      von anderen 
beobachtet
Nächtliche Wadenkrämpfe Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Nächtliches Zähneknirschen Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Sprechen während des Schlafes Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Verschlucken während des Schlafes oder 
Erwachen mit dem Gefühl zu ersticken

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet




 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Einnässen während des Schlafes 
Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Blatt bitte wenden
Seite 2/2 Früher Aktuell
Wie häufig treten folgende 































Woher wissen Sie, 
dass dieses Verhalten 
bei Ihnen auftritt?
Bemerkungen
Furchteinflössende Träume oder Albträume Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Erwachen mit massiver Angst und 




 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet




 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Im Schlaf (also unbewußt) etwas essen oder 
eine Mahlzeit zubereiten, die auch 
ungewöhnliche oder ungenießbare Zutaten 




 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Erwachen mit starker 




 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Erwachen mit einer Lähmung des ganzen 
Körpers (bis auf Augen und Atmung), die 
mehrere Sekunden dauern kann

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Schlafwandeln oder sich aus dem Schlaf heraus 
aufrichten, ohne das Bett zu verlassen

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Kommt es vor, dass Sie während des Schlafes 
um sich schlagen oder –treten?

Noch nie
 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Kommt es vor, dass Sie das, was Sie träumen, 




 vor ____ 
Jahren, jetzt 
nicht mehr
    
 selbst beobachtet
 von anderen 
beobachtet
Andere außergewöhnliche Verhaltensweisen 
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 Beispiel Stärkegrad 
  
Frage: Wie sehr litten Sie unter  
           Rückenschmerzen? 
 
 
Wenn bei Ihnen als Antwort auf diese Frage am 
besten „sehr stark“ zutrifft, so kreuzen Sie das 




























      X
Anleitung 
Sie finden nachstehend eine Liste von Problemen und 
Beschwerden, die man manchmal hat. Bitte lesen Sie jede Frage 
sorgfältig durch und entscheiden Sie, wie stark Sie während der 
vergangenen 7 Tage bis heute durch diese Beschwerden gestört 
oder bedrängt worden sind. Überlegen Sie bitte nicht erst, welche 
Antwort „den besten Eindruck“ machen könnte, sondern antworten 
Sie so, wie es für Sie persönlich zutrifft. Machen Sie bitte hinter jeder 
Frage nur ein Kreuz in das Kästchen mit der für Sie am besten 
zutreffenden Antwort. Streichen Sie versehentliche Antworten 
deutlich durch, und kreuzen Sie danach das richtige Kästchen an. 
Bitte beantworten Sie jede Frage!  ALLE  IHRE  ANTWORTEN  WERDEN  VERTRAULICH  BEHANDELT. 































































1. Kopfschmerzen       25. Befürchtungen, wenn Sie allein      
2. Nervosität oder innerem Zittern       
aus dem Haus gehen 
     
3. immer wieder auftauchenden unange-       26. Selbstvorwürfen über bestimmte Dinge      
 
nehmen Gedanken, Worten oder Ideen, 
die Ihnen nicht aus dem Kopf gehen       27. Kreuzschmerzen      
4. Ohnmachts- oder Schwindelgefühlen       28. dem Gefühl, dass es Ihnen schwer fällt,      
5.  Verminderung Ihres Interesses oder       
etwas anzufangen 
     
 
Ihrer Freude an Sexualität 
      29. Einsamkeitsgefühlen      
6. allzu kritischer Einstellung gegenüber anderen       30. Schwermut      
7. der Idee, dass irgend jemand Macht über       31. dem Gefühl, sich zu viele Sorgen machen      
 
Ihre Gedanken hat 
      
zu müssen 
     
8. dem Gefühl, dass andere an den meisten        32. dem Gefühl, sich für nichts zu      
 
Ihrer Schwierigkeiten Schuld sind 
      
interessieren 
     
9. Gedächtnisschwierigkeiten       33. Furchtsamkeit      
10. Beunruhigung wegen Achtlosigkeit und       34. Verletzlichkeit in Gefühlsdingen      
 
Nachlässigkeit 
      35. der Idee, dass andere Leute von Ihren      
11. dem Gefühl, leicht reizbar oder verärgerbar       
geheimsten Gedanken wissen 
     
 
zu sein 
      36. dem Gefühl, dass andere Sie nicht      
12. Herz- und Brustschmerzen       
verstehen oder teilnahmslos sind 
     
13. Furcht auf offenen Plätzen oder auf       37. dem Gefühl, dass die Leute unfreundlich      
 
der Straße 
      
sind oder Sie nicht leiden können 
     
14. Energielosigkeit oder Verlangsamung in       38. der Notwendigkeit, alles sehr langsam zu      
 
den Bewegungen oder im Denken 
      
zu tun, um sicher zu sein, dass alles 
richtig wird      
15. Gedanken, sich das Leben zu nehmen       39. Herzklopfen oder Herzjagen      
16. Hören von Stimmen, die sonst keiner hört       40. Übelkeit oder Magenverstimmung      
17. Zittern       41. Minderwertigkeitsgefühlen gegenüber      
18. dem Gefühl, dass man den meisten Leuten       
anderen 
     
 
nicht trauen kann 
      42. Muskelschmerzen (Muskelkater,      
19. schlechtem Appetit       
Gliederreißen) 
     
20. Neigung zum Weinen       43. dem Gefühl, dass andere Sie beobachten      
21. Schüchternheit oder Unbeholfenheit im       
oder über Sie reden 
     
 
Umgang mit dem anderen Geschlecht 
      44. Einschlafschwierigkeiten      
22. der Befürchtung, ertappt oder erwischt       45. dem Zwang, wieder und wieder nachzu-      
 
zu werden 
      
kontrollieren, was Sie tun 
     
23. plötzlichem Erschrecken ohne Grund       46. Schwierigkeiten sich zu entscheiden      
24. Gefühlsausbrüchen, denen gegenüber       47. Furcht vor Fahrten in Bus, Straßenbahn,      
 
Sie machtlos waren 
      
U-Bahn oder Zug 
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48. Schwierigkeiten beim Atmen       71. einem Gefühl, dass alles sehr        
 
 
      
anstrengend ist 
      
49. Hitzewallungen oder Kälteschauern       72. Schreck- oder Panikanfälle       
 
 
      73. Unbehagen beim Essen oder Trinken in        
50. die Notwendigkeit, bestimmte Dinge, Orte       
der Öffentlichkeit 
      
 
oder Tätigkeiten zu meiden, weil Sie durch 
diese erschreckt werden       74. der Neigung, immer wieder in       
51. Leere im Kopf       
Erörterungen und Auseinander- 
setzungen zu geraten       
52. Taubheit oder Kribbeln in einzelnen       75. Nervosität, wenn Sie allein gelassen        
 
Körperteilen 
      
werden 
      
53. dem Gefühl, einen Klumpen (Kloß) im Hals       76. mangelnder Anerkennung Ihrer        
 
zu haben 
      
Leistungen durch andere 
      
54. einem Gefühl der Hoffnungslosigkeit ange-        77. Einsamkeitsgefühlen, selbst wenn Sie in       
 
sichts der Zukunft 
      
Gesellschaft sind 
      
55. Konzentrationsschwierigkeiten       78. so starker Ruhelosigkeit, dass Sie nicht       
56. Schwächegefühl in einzelnen Körperteilen       
stillsitzen können 
      
57. dem Gefühl, gespannt oder aufgeregt       79. dem Gefühl, wertlos zu sein       
 
zu sein 
      80. dem Gefühl, dass Ihnen etwas Schlimmes       
58. Schweregefühl in Armen oder Beinen       passieren wird       
59. Gedanken an den Tod und an das Sterben       81. dem Bedürfnis, laut zu schreien oder mit       
60. dem Drang sich zu überessen       
Gegenständen zu werfen 
      
61. einem unbehaglichen Gefühl, wenn Leute       82. der Furcht, in der Öffentlichkeit in Ohn-       
 
Sie beobachten oder über Sie reden 
      
macht zu fallen 
      
62. dem Auftauchen von Gedanken, die nicht       83. dem Gefühl, dass die Leute Sie ausnut-       
 
Ihre eigenen sind 
      
zen, wenn Sie es zulassen würden 
      
63. dem Drang, jemanden zu schlagen, zu ver-       84. sexuellen Vorstellungen, die ziemlich       
 
letzen oder ihm Schmerzen zuzufügen 
      
unangenehm für Sie sind 
      
64. frühem Erwachen am Morgen       85. dem Gedanken, dass Sie für Ihre Sünden       
65. zwanghafter Wiederholung derselben Tätig-       
bestraft werden sollten 
      
 
keiten wie Berühren, Zählen, Waschen 
      86. schreckerregenden Gedanken und       
66. unruhigem oder gestörtem Schlaf       Vorstellungen       
67. dem Drang, Dinge zu zerbrechen oder zu       87. dem Gedanken, dass etwas ernstlich mit       
 
zerschmettern 
      
Ihrem Körper nicht in Ordnung ist 
      
68. Ideen oder Anschauungen, die andere nicht       88. dem Eindruck, sich einer anderen Person       
 
mit Ihnen teilen 
      
nie so richtig nahe fühlen zu können 
      
69. starker Befangenheit im Umgang mit       89. Schuldgefühlen       
 
anderen 
             
70. Abneigung gegen Menschenmengen, z.B.       90. dem Gedanken, dass irgend etwas mit       
 
beim Einkaufen oder im Kino 
      
Ihrem Verstand nicht in Ordnung ist 
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